

Interleukin-6 Receptor Antagonists in Critically Ill Patients

New England Journal of Medicine

384, 1491-1502

DOI: [10.1056/nejmoa2100433](https://doi.org/10.1056/nejmoa2100433)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Drug treatments for covid-19: living systematic review and network meta-analysis. <i>BMJ</i> , The, 2020, 370, m2980. | 3.0 | 592 |
| 2 | How should we use convalescent plasma therapies for the management of COVID-19?. <i>Blood</i> , 2021, 137, 1573-1581. | 0.6 | 29 |
| 4 | Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab031. | 0.3 | 7 |
| 5 | Update: Drug treatment options for coronavirus disease 2019 (COVID-19). <i>BioScience Trends</i> , 2021, 15, 345-349. | 1.1 | 5 |
| 6 | Pharmacologic Treatment of COVID-19: Evidence-Based Update. <i>Indian Journal of Respiratory Care</i> , 2021, 10, S34-S38. | 0.1 | 3 |
| 7 | Japanese rapid/living recommendations on drug management for COVID-19. <i>Acute Medicine & Surgery</i> , 2021, 8, e664. | 0.5 | 12 |
| 8 | Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs. <i>Rheumatology</i> , 2021, 60, vi12-vi20. | 0.9 | 26 |
| 9 | COVID-19 and Sepsis. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 3301-3311. | 0.4 | 37 |
| 10 | Modulating the host immune response to fight against COVID-19: Where are we in 2021?. <i>Virulence</i> , 2021, 12, 1732-1736. | 1.8 | 8 |
| 11 | Efficacy and Safety of IL-6 Inhibitors in Patients with COVID-19 Pneumonia: A Systematic Review and Meta-Analysis of Multicentre, Randomised Trials. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 12 | Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358. | 0.4 | 3 |
| 13 | Infrared light therapy relieves TLR-4 dependent hyper-inflammation of the type induced by COVID-19. <i>Communicative and Integrative Biology</i> , 2021, 14, 200-211. | 0.6 | 8 |
| 14 | Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1839-1848. | 1.9 | 176 |
| 15 | Host directed therapies: COVID-19 and beyond. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100058. | 1.7 | 19 |
| 16 | Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 803-815. | 0.5 | 31 |
| 17 | The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1089-1094. | 0.8 | 25 |
| 18 | Comparing Clinical Features and Outcomes in Mechanically Ventilated Patients with COVID-19 and Acute Respiratory Distress Syndrome. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1876-1885. | 1.5 | 34 |
| 19 | SARS-CoV-2 infection: molecular mechanisms of severe outcomes to suggest therapeutics. <i>Expert Review of Proteomics</i> , 2021, 18, 105-118. | 1.3 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 20 | EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 698-706. | 0.5 | 37 |
| 21 | Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1062-1070. | 0.7 | 23 |
| 22 | Tocilizumab for hospitalized patients with COVID-19. <i>Cmaj</i> , 2021, 193, E521-E521. | 0.9 | 3 |
| 23 | Interleukin-6 blocking agents for treating COVID-19: a living systematic review. <i>The Cochrane Library</i> , 2021, 2021, CD013881. | 1.5 | 106 |
| 24 | Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities. <i>Frontiers in Immunology</i> , 2021, 12, 663586. | 2.2 | 26 |
| 25 | COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions. <i>RMD Open</i> , 2021, 7, e001638. | 1.8 | 9 |
| 26 | The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic. <i>Clinical Medicine</i> , 2021, 21, e287-e289. | 0.8 | 1 |
| 28 | Current evidence for COVID-19 therapies: a systematic literature review. <i>European Respiratory Review</i> , 2021, 30, 200384. | 3.0 | 37 |
| 29 | Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. <i>Science Immunology</i> , 2021, 6, . | 5.6 | 161 |
| 30 | Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2021, 8, 127-139. | 0.9 | 31 |
| 32 | Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048. | 3.1 | 152 |
| 34 | Terapia combinada de tocilizumab y corticoides en la enfermedad grave por SARS-CoV-2. <i>Medicina Intensiva</i> , 2021, , . | 0.4 | 2 |
| 35 | Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3059. | 1.8 | 36 |
| 36 | <scp>COVID</scp>â€19: immunopathology, pathophysiological mechanisms, and treatment options. <i>Journal of Pathology</i> , 2021, 254, 307-331. | 2.1 | 86 |
| 37 | Vitamin D₃ to Treat COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1047. | 3.8 | 30 |
| 38 | Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab151. | 0.4 | 19 |
| 39 | Repositioned Drugs for COVID-19â€the Impact on Multiple Organs. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1484-1501. | 0.3 | 3 |
| 40 | Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. <i>Reviews in Medical Virology</i> , 2022, 32, e2239. | 3.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 41 | Platform Trials â€” Beware the Noncomparable Control Group. <i>New England Journal of Medicine</i> , 2021, 384, 1572-1573. | 13.9 | 53 |
| 43 | Interleukin-6 Receptor Inhibition in Covid-19 â€” Cooling the Inflammatory Soup. <i>New England Journal of Medicine</i> , 2021, 384, 1564-1565. | 13.9 | 118 |
| 44 | What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. <i>PLoS ONE</i> , 2021, 16, e0249349. | 1.1 | 12 |
| 45 | The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1389-1392. | 1.1 | 0 |
| 46 | Response to: â€”Correspondence on â€”Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC studyâ€”â€” by Kaklamanos<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e135-e135. | 0.5 | 0 |
| 49 | From bedside to bench: regulation of host factors in SARS-CoV-2 infection. <i>Experimental and Molecular Medicine</i> , 2021, 53, 483-494. | 3.2 | 6 |
| 50 | Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceuticals. <i>Pharmaceutics</i> , 2021, 13, 494. | 2.0 | 3 |
| 51 | Evolution of the Human Cytokine Response from Acute Illness to Disease Resolution in SARS-Cov-2 Infectionâ€”Implications for Therapeutic Monitoring and Therapeutic Targets. <i>Journal of Clinical Immunology</i> , 2021, 41, 1162-1164. | 2.0 | 2 |
| 52 | Two Key Takeaways From a Year of Pandemic Research. <i>Critical Care Medicine</i> , 2021, Publish Ahead of Print, 1223-1226. | 0.4 | 1 |
| 53 | Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan. <i>Journal of Intensive Care</i> , 2021, 9, 34. | 1.3 | 3 |
| 54 | IL-6 modulation for COVID-19: the right patients at the right time?. , 2021, 9, e002285. | | 32 |
| 55 | Neurological update: COVID-19. <i>Journal of Neurology</i> , 2021, 268, 4379-4387. | 1.8 | 25 |
| 59 | Tocilizumab en el paciente con COVID-19. <i>Medicina ClÃnica</i> , 2021, 156, 402-406. | 0.3 | 0 |
| 60 | A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 675-686. | 1.4 | 22 |
| 61 | Is IL-6 a key cytokine target for therapy in COVID-19?. <i>Nature Reviews Immunology</i> , 2021, 21, 337-339. | 10.6 | 102 |
| 64 | Simultaneous Inhibition of Three Major Cytokines and Its Therapeutic Effects: A Peptide-Based Novel Therapy against Endotoxemia in Mice. <i>Journal of Personalized Medicine</i> , 2021, 11, 436. | 1.1 | 5 |
| 65 | Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials. <i>Lung</i> , 2021, 199, 239-248. | 1.4 | 24 |
| 66 | The role of IL-6 and IL-6 blockade in COVID-19. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 601-618. | 1.3 | 62 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 67 | Strongyloidiasis in the COVID era: a warning for an implementation of the screening protocol. <i>Infection</i> , 2021, 49, 1065-1067. | 2.3 | 4 |
| 68 | Infection-induced inflammation from specific inborn errors of immunity to COVID-19. <i>FEBS Journal</i> , 2021, 288, 5021-5041. | 2.2 | 12 |
| 69 | Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. <i>Cell Discovery</i> , 2021, 7, 37. | 3.1 | 11 |
| 70 | Patients with COVID-19: in the dark-NETs of neutrophils. <i>Cell Death and Differentiation</i> , 2021, 28, 3125-3139. | 5.0 | 189 |
| 71 | Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome. <i>Cell Reports Medicine</i> , 2021, 2, 100269. | 3.3 | 41 |
| 72 | Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 522-532. | 5.2 | 195 |
| 73 | Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146. | 0.5 | 151 |
| 74 | Tailored modulation of the inflammatory balance in COVID-19 patients admitted to the ICU—a viewpoint. <i>Critical Care</i> , 2021, 25, 178. | 2.5 | 4 |
| 75 | Prognostic Factors in Hospitalized COVID-19 Patients at the Start of the Pandemic in Colombia: A Retrospective Cohort Study. <i>Cureus</i> , 2021, 13, e14865. | 0.2 | 2 |
| 77 | Key Factors Fuelling India's Second COVID Surge. <i>The Physician</i> , 2021, 7, 1-6. | 0.2 | 1 |
| 78 | Time for tocilizumab in COVID-19?. <i>Intensive Care Medicine</i> , 2021, 47, 692-694. | 3.9 | 8 |
| 79 | Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. <i>Medicina Clínica</i> , 2022, 158, 301-307. | 0.3 | 4 |
| 80 | Practice of adjunctive treatments in critically ill COVID-19 patients—rational for the multicenter observational PROAcT-COVID study in The Netherlands. <i>Annals of Translational Medicine</i> , 2021, 9, 813-813. | 0.7 | 6 |
| 81 | Promising Immunotherapies against COVID-19. <i>Advanced Therapeutics</i> , 2021, 4, 2100044. | 1.6 | 4 |
| 82 | The Relevance of Monoclonal Antibodies in the Treatment of COVID-19. <i>Vaccines</i> , 2021, 9, 557. | 2.1 | 10 |
| 84 | Tocilizumab in COVID-19: some clarity amid controversy. <i>Lancet</i> , 2021, 397, 1599-1601. | 6.3 | 29 |
| 85 | Where are we with drug treatments for covid-19?. <i>BMJ</i> , 2021, 373, n1109. | 3.0 | 12 |
| 86 | Reply to Cheng et al.: COVID-19 induces lower extent of cytokines, but damages vascular endothelium by IL-6 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2105040118. | 3.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 87 | HGF, IL-1 β , and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2017. | 1.0 | 34 |
| 88 | Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. <i>Infectious Diseases of Poverty</i> , 2021, 10, 71. | 1.5 | 42 |
| 89 | Tocilizumab in the treatment of COVID-19—a meta-analysis. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 577-586. | 0.2 | 13 |
| 90 | Managing drug shortages during a pandemic: tocilizumab and COVID-19. <i>Cmaj</i> , 2021, 193, E771-E776. | 0.9 | 12 |
| 91 | Cytokine Blockade in Coronavirus Disease 2019: Keeping an Open Mind. , 2021, 3, e0424. | | 0 |
| 92 | Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. <i>European Journal of Medical Research</i> , 2021, 26, 41. | 0.9 | 32 |
| 93 | COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. <i>Immunological Reviews</i> , 2021, 302, 228-240. | 2.8 | 126 |
| 94 | Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2841-2850. | 1.4 | 15 |
| 95 | Improving the Outcomes of Immunocompromised Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, 73, e1397-e1401. | 2.9 | 44 |
| 97 | Combination Therapy With Tocilizumab and Dexamethasone Cost-Effectively Reduces Coronavirus Disease 2019 Mortality. <i>Clinical Infectious Diseases</i> , 2021, 73, 2116-2118. | 2.9 | 13 |
| 98 | Predisposition of COVID-19 patients to secondary infections. <i>Current Opinion in Infectious Diseases</i> , 2021, Publish Ahead of Print, 357-364. | 1.3 | 5 |
| 99 | It Is Time to Determine Tocilizumab's Place in Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2021, , . | 2.9 | 1 |
| 100 | Diagnosis and management of acute respiratory distress syndrome. <i>Cmaj</i> , 2021, 193, E761-E768. | 0.9 | 21 |
| 101 | International COVID-19 trial to restart with focus on immune responses. <i>Nature</i> , 2021, , . | 13.7 | 11 |
| 102 | Monitoring clinical trials in infectious diseases. , 2021, 2, 29-32. | | 0 |
| 103 | Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a Systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 5527-5537. | 0.9 | 36 |
| 105 | Coronavirus Disease 2019 and Kidney Transplantation in Saudi Arabia: Outcomes and Future Opportunities. <i>Annals of Transplantation</i> , 2021, 26, e931832. | 0.5 | 6 |
| 106 | Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , 2021, 47, 819-834. | 3.9 | 106 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 108 | COVID-19 pneumonia in Galicia (Spain): Impact of prognostic factors and therapies on mortality and need for mechanical ventilation. PLoS ONE, 2021, 16, e0253465. | 1.1 | 1 |
| 110 | The role of antirheumatics in patients with COVID-19. Lancet Rheumatology, The, 2021, 3, e447-e459. | 2.2 | 36 |
| 111 | Biomarkers for severe COVID-19. EBioMedicine, 2021, 68, 103405. | 2.7 | 5 |
| 112 | Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respiratory Medicine, the, 2021, 9, 643-654. | 5.2 | 120 |
| 113 | Clinical Management of COVID-19 Patients â€” An Update. Seminars in Nuclear Medicine, 2022, 52, 4-10. | 2.5 | 33 |
| 115 | A lethal mouse model using a mouse-adapted SARS-CoV-2 strain with enhanced binding to mouse ACE2 as an important platform for COVID-19 research. EBioMedicine, 2021, 68, 103406. | 2.7 | 4 |
| 116 | Future developments in the prevention, diagnosis and treatment of COVID-19. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2021, 73, 56-80. | 1.4 | 4 |
| 117 | Impact of intermediate to high doses of methylprednisolone on mortality rate in patients with COVID-19 pneumoniaâ€”induced severe systemic inflammation. International Journal of Clinical Practice, 2021, 75, e14479. | 0.8 | 6 |
| 118 | Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk. Annals of Pharmacotherapy, 2021, , 106002802110288. | 0.9 | 7 |
| 119 | HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. Current HIV/AIDS Reports, 2021, 18, 261-270. | 1.1 | 5 |
| 120 | Tocilizumab en el tratamiento de la neumonÃa por SARS-CoV-2: anÃlisis de una cohorte retrospectiva pareada. Medicina ClÃnica, 2021, , . | 0.3 | 2 |
| 122 | Back to the future with machine learning. Nature Machine Intelligence, 2021, 3, 464-465. | 8.3 | 0 |
| 124 | Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. ELife, 2021, 10, . | 2.8 | 21 |
| 125 | Australia needs a prioritised national research strategy for clinical trials in a pandemic: lessons learned from COVID-19. Medical Journal of Australia, 2021, 215, 56. | 0.8 | 5 |
| 126 | Preventing Infectious Complications of Immunomodulation in COVID-19 in Foreign-Born Patients. Journal of Immigrant and Minority Health, 2021, 23, 1343-1347. | 0.8 | 2 |
| 127 | Accelerating the Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: A Risk of Combining Dexamethasone and Tocilizumab for Severe Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 224, 934-937. | 1.9 | 6 |
| 128 | Hospital-Acquired Bloodstream Infections in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (Coronavirus Disease 2019): Association With Immunosuppressive Therapies. Open Forum Infectious Diseases, 2021, 8, ofab339. | 0.4 | 22 |
| 129 | Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?. Cardiovascular Drugs and Therapy, 2022, 36, 547-560. | 1.3 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 130 | Risk factors for mortality in critically ill patients with COVID-19: a multicenter retrospective case-control study. <i>BMC Infectious Diseases</i> , 2021, 21, 602. | 1.3 | 14 |
| 131 | Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. <i>Lancet Respiratory Medicine</i> , 2021, 9, 655-664. | 5.2 | 88 |
| 132 | Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome. <i>Viruses</i> , 2021, 13, 1067. | 1.5 | 7 |
| 133 | Dexamethasone for Severe COVID-19: How Does It Work at Cellular and Molecular Levels?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6764. | 1.8 | 25 |
| 135 | Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. <i>Medicina Clínica</i> , 2022, 158, 509-518. | 0.3 | 4 |
| 136 | The Right Ventricle in COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 2535. | 1.0 | 21 |
| 137 | Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1407-1418. | 1.8 | 5 |
| 138 | COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. <i>Journal of Clinical Immunology</i> , 2021, 41, 1463-1478. | 2.0 | 40 |
| 139 | Immunotherapy in COVID-19: why, who, and when?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 549-551. | 5.2 | 5 |
| 141 | Update in COVID-19 2020. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1462-1471. | 2.5 | 13 |
| 142 | Therapeutic Agents Rounding Up the Immunopathology of COVID-19. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 657-668. | 0.9 | 2 |
| 143 | Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Rheumatology</i> , 2021, 3, e410-e418. | 2.2 | 57 |
| 145 | Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic. <i>Metabolism Open</i> , 2021, 10, 100096. | 1.4 | 27 |
| 146 | Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108. | 13.5 | 309 |
| 147 | Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. <i>Immunity</i> , 2021, 54, 1186-1199.e7. | 6.6 | 71 |
| 148 | COVID-19 Summary Guidelines. <i>Sushruta Journal of Health Policy & Opinions</i> , 2021, 14, 1-5. | 0.1 | 0 |
| 149 | Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. <i>Current Opinion in Rheumatology</i> , 2021, 33, 409-411. | 2.0 | 0 |
| 151 | The impact of COVID-19 on pregnancy and therapeutic drug development. <i>British Journal of Pharmacology</i> , 2022, 179, 2108-2120. | 2.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 153 | Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. <i>Scientific Reports</i> , 2021, 11, 12414. | 1.6 | 14 |
| 154 | The solid organ transplant recipient with SARS-CoV-2 infection. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 412-418. | 0.8 | 5 |
| 155 | Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN- β . <i>Journal of Clinical Immunology</i> , 2021, 41, 1425-1442. | 2.0 | 39 |
| 156 | COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?. <i>Transplantation</i> , 2021, 105, 2146-2155. | 0.5 | 25 |
| 157 | Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. <i>Bioscience Reports</i> , 2021, 41, . | 1.1 | 18 |
| 159 | Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3419-3428. | 1.6 | 25 |
| 160 | The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2021, 96, 107602. | 1.7 | 18 |
| 161 | COVID-19 and Kidney Transplantation. <i>Transplantation</i> , 2021, 2, 288-290. | 0.3 | 0 |
| 162 | Differences in Inflammatory Marker Kinetics between the First and Second Wave of COVID-19 Patients Admitted to the ICU: A Retrospective, Single-Center Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3290. | 1.0 | 7 |
| 164 | Tocilizumab in patients with COVID-19: which patient, time, and dose?. <i>Journal of Anesthesia</i> , 2021, 35, 896-902. | 0.7 | 7 |
| 165 | Extracorporeal hemocorrection methods for COVID-19: are there outlooks?. <i>Nephrology (Saint-Petersburg)</i> , 2021, 25, 95-106. | 0.1 | 0 |
| 166 | Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. <i>Current Opinion in Rheumatology</i> , 2021, 33, 419-430. | 2.0 | 53 |
| 167 | Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 593-596. | 0.1 | 1 |
| 168 | The role of immunomodulatory medications in the treatment of COVID-19. <i>Current Opinion in Rheumatology</i> , 2021, 33, 431-445. | 2.0 | 4 |
| 169 | Ultrasound and Microbubbles for Targeted Drug Delivery to the Lung Endothelium in ARDS: Cellular Mechanisms and Therapeutic Opportunities. <i>Biomedicines</i> , 2021, 9, 803. | 1.4 | 15 |
| 171 | Interleukin-6 and intrapulmonary shunt. <i>European Respiratory Journal</i> , 2021, 58, 2101292. | 3.1 | 3 |
| 172 | Iron metabolism in infections: Focus on COVID-19. <i>Seminars in Hematology</i> , 2021, 58, 182-187. | 1.8 | 47 |
| 173 | Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <i>Intensive Care Medicine</i> , 2021, 47, 867-886. | 3.9 | 65 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 174 | COVID-19 and immunothrombosis: emerging understanding and clinical management. <i>British Journal of Haematology</i> , 2021, 194, 518-529. | 1.2 | 42 |
| 175 | The future of acute and emergency care. <i>Future Healthcare Journal</i> , 2021, 8, e230-e236. | 0.6 | 1 |
| 176 | Editorial: Hemostatic Challenges in Pediatric Critical Care Medicine. <i>Frontiers in Pediatrics</i> , 2021, 9, 697921. | 0.9 | 0 |
| 178 | Tocilizumab and SARS-CoV-2 (COVID-19): An Evolving Story, the Picture Is Clearer. <i>Infectious Diseases in Clinical Practice</i> , 2021, 29, e199-e201. | 0.1 | 0 |
| 179 | COVID-19 pneumonia. <i>Nurse Practitioner</i> , 2021, 46, 22-28. | 0.2 | 0 |
| 180 | Targeting cytokine storm in COVID-19: what have we learned?. <i>European Heart Journal Open</i> , 2021, 1, . | 0.9 | 3 |
| 181 | Does adjunctive hemoadsorption with CytoSorb affect survival of COVID-19 patients on ECMO? A critical statement. <i>Journal of Critical Care</i> , 2021, 66, 187-188. | 1.0 | 9 |
| 182 | Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). <i>Infectious Diseases and Therapy</i> , 2021, 10, 1837-1885. | 1.8 | 28 |
| 183 | Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19. <i>Cell Host and Microbe</i> , 2021, 29, 1052-1062. | 5.1 | 185 |
| 184 | Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections. <i>F1000Research</i> , 0, 10, 536. | 0.8 | 6 |
| 185 | Cytokine adsorption during ECMO for COVID-19-related ARDS. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 680-682. | 5.2 | 3 |
| 186 | Pathophysiology of COVID-19-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2021, 17, 751-764. | 4.1 | 280 |
| 187 | How trustworthy guidelines can impact outcomes. <i>Current Opinion in Critical Care</i> , 2021, 27, 544-550. | 1.6 | 4 |
| 188 | Distinctive features of severe SARS-CoV-2 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, . | 3.9 | 49 |
| 189 | Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation. <i>European Heart Journal Open</i> , 2021, 1, . | 0.9 | 19 |
| 191 | Re: "Methodological evaluation of bias in observational COVID-19 studies on drug effectiveness"™ by Wolkewitz et al.. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1043-1044. | 2.8 | 0 |
| 194 | Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review. , 2021, 3, e0492. | | 6 |
| 196 | Critical care outcomes from COVID-19: patients, interventions, healthcare systems and the need for core datasets. <i>Anaesthesia</i> , 2021, 76, 1155-1158. | 1.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 197 | Contemporary narrative review of treatment options for COVID-19. <i>Respirology</i> , 2021, 26, 745-767. | 1.3 | 12 |
| 198 | Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. <i>Experimental and Molecular Medicine</i> , 2021, 53, 1116-1123. | 3.2 | 116 |
| 199 | Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2291-2307. | 1.8 | 12 |
| 200 | High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. <i>Life Science Alliance</i> , 2021, 4, e202001009. | 1.3 | 8 |
| 202 | What every intensivist should know about Tocilizumab. <i>Critical Care</i> , 2021, 25, 262. | 2.5 | 10 |
| 205 | Immune Intervention in Sepsis. <i>Frontiers in Pharmacology</i> , 2021, 12, 718089. | 1.6 | 21 |
| 206 | Antimicrobial immunotherapeutics: past, present and future. <i>Emerging Topics in Life Sciences</i> , 2021, 5, 609-628. | 1.1 | 1 |
| 207 | What we learned in the past year in managing our COVID-19 patients in intensive care units?. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 81-101. | 0.8 | 5 |
| 208 | Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1195-1213. | 1.8 | 14 |
| 209 | The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2. <i>Journal of Osteopathic Medicine</i> , 2021, 121, 705-714. | 0.4 | 6 |
| 210 | Secondary pneumonias in critically ill patients with COVID-19: risk factors and outcomes. <i>Current Opinion in Critical Care</i> , 2021, 27, 468-473. | 1.6 | 15 |
| 211 | Key summary of German national treatment guidance for hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 93-106. | 2.3 | 30 |
| 212 | A single-center experience in use of tocilizumab in COVID-19 pneumonia in India. <i>Medical Journal Armed Forces India</i> , 2021, 77, S296-S304. | 0.3 | 2 |
| 215 | COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993. | 1.8 | 136 |
| 216 | COVID-19 and Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 328-333. | 1.0 | 7 |
| 217 | JAK Inhibitors "More Than Just Glucocorticoids. <i>New England Journal of Medicine</i> , 2021, 385, 463-465. | 13.9 | 15 |
| 218 | Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19. <i>Medical Science Monitor</i> , 2021, 27, e933973. | 0.5 | 6 |
| 219 | The COVID-19 world "Are we there yet?. <i>Journal of Diabetes Investigation</i> , 2021, 12, 1125-1127. | 1.1 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 220 | COVID-19 multidisciplinary working group. <i>Clinical Medicine</i> , 2021, 21, e429-e430. | 0.8 | 0 |
| 221 | Efficacy of tocilizumab in COVID-19: A review of the current evidence. <i>Science Progress</i> , 2021, 104, 003685042110303. | 1.0 | 6 |
| 222 | Efficacy and Safety of Tocilizumab Treatment COVID-19 Patients: A Case-Control Study and Meta-Analysis. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1677-1698. | 1.8 | 2 |
| 223 | Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, e41-e45. | 0.5 | 9 |
| 224 | Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110282. | 0.5 | 1 |
| 225 | Methylprednisolone and 60 Days in Hospital Survival in Coronavirus Disease 2019 Pneumonia. , 2021, 3, e0493. | | 9 |
| 227 | Coronavirus disease 2019 in children. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 500-509. | 1.3 | 8 |
| 229 | Myocarditis associated with Covid-19 disease: A systematic review of published case reports and case series. <i>International Journal of Clinical Practice</i> , 2021, 75, e14470. | 0.8 | 55 |
| 230 | Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506. | 2.2 | 58 |
| 232 | Trends in 28-Day Mortality of Critical Care Patients With Coronavirus Disease 2019 in the United Kingdom: A National Cohort Study, March 2020 to January 2021*. <i>Critical Care Medicine</i> , 2021, 49, 1895-1900. | 0.4 | 18 |
| 234 | Four consecutive yearly point-prevalence studies in Wales indicate lack of improvement in sepsis care on the wards. <i>Scientific Reports</i> , 2021, 11, 16222. | 1.6 | 2 |
| 235 | Circulating Osteopontin Levels and Outcomes in Patients Hospitalized for COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 3907. | 1.0 | 17 |
| 238 | Cytokine levels in sputum, not serum, may be more helpful for indicating the damage in the lung and the prognosis of severe COVID-19 – A case series. <i>Journal of Infection</i> , 2021, 83, e6-e9. | 1.7 | 6 |
| 239 | SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications. <i>Current Cardiology Reports</i> , 2021, 23, 129. | 1.3 | 17 |
| 240 | Cardiovascular Disease Complicating COVID-19 in the Elderly. <i>Medicina (Lithuania)</i> , 2021, 57, 833. | 0.8 | 9 |
| 241 | COVID-19: Inflammatory Profile. <i>Annual Review of Medicine</i> , 2022, 73, 65-80. | 5.0 | 43 |
| 242 | Clinical efficacy and safety of combination therapy of tocilizumab and steroid pulse therapy for critical COVID-19 in HD patients. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 75-85. | 0.7 | 13 |
| 243 | Correspondence on –Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry –by Sparks<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e157-e157. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 244 | The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. PLoS ONE, 2021, 16, e0251378. | 1.1 | 3 |
| 245 | Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. European Respiratory Journal, 2022, 59, 2101724. | 3.1 | 38 |
| 246 | Risk of COVID-19 in shielded and nursing care home patients: a cohort study in general practice. BJGP Open, 2021, 5, BJGPO.2021.0081. | 0.9 | 4 |
| 247 | The "cytokine storm": molecular mechanisms and therapeutic prospects. Trends in Immunology, 2021, 42, 681-705. | 2.9 | 156 |
| 248 | Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19: Mechanisms and Therapeutic Targets. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-15. | 1.9 | 66 |
| 249 | Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy. International Journal of Molecular Sciences, 2021, 22, 8663. | 1.8 | 18 |
| 250 | Efficacy of convalescent plasma for treatment of COVID-19 in Uganda. BMJ Open Respiratory Research, 2021, 8, e001017. | 1.2 | 30 |
| 251 | Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients. Critical Care, 2021, 25, 281. | 2.5 | 50 |
| 252 | How COVID-19 will change the management of other respiratory viral infections. Intensive Care Medicine, 2021, 47, 1148-1151. | 3.9 | 1 |
| 253 | Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Annals of Internal Medicine, 2021, 174, 1151-1158. | 2.0 | 16 |
| 254 | Pressing Questions and Challenges in the HIV-1 and SARS-CoV-2 Syndemic. AIDS Research and Human Retroviruses, 2021, 37, 589-600. | 0.5 | 5 |
| 255 | Antirheumatic drugs and COVID-19: frustrations and hopes. Meditsinskiy Sovet, 2021, , 134-139. | 0.1 | 0 |
| 256 | Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al. Annals of the Rheumatic Diseases, 2023, 82, e158-e158. | 0.5 | 3 |
| 257 | Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab. Acta Microbiologica Et Immunologica Hungarica, 2021, , . | 0.4 | 7 |
| 258 | MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management. European Journal of Endocrinology, 2021, 185, R103-R111. | 1.9 | 13 |
| 259 | Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. Frontiers in Microbiology, 2021, 12, 637554. | 1.5 | 8 |
| 260 | Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clinical Microbiology and Infection, 2021, 27, 1076-1082. | 2.8 | 28 |
| 261 | Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. Nature Communications, 2021, 12, 5152. | 5.8 | 47 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 262 | Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 499. | 3.8 | 498 |
| 264 | Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19. <i>Thorax</i> , 2022, 77, 203-209. | 2.7 | 90 |
| 265 | Don't close the book on tocilizumab for the treatment of severe COVID-19 pneumonia—the jury is still out: The Kuwait experience. <i>PLoS ONE</i> , 2021, 16, e0254379. | 1.1 | 2 |
| 266 | Mortality in Cancer Patients With COVID-19 Who Are Admitted to an ICU or Who Have Severe COVID-19: A Systematic Review and Meta-Analysis. <i>JCO Global Oncology</i> , 2021, 7, 1286-1305. | 0.8 | 30 |
| 267 | Defining Potential Therapeutic Targets in Coronavirus Disease 2019: A Cross-Sectional Analysis of a Single-Center Cohort. , 2021, 3, e0488. | | 2 |
| 268 | Predictive Immunological, Virological, and Routine Laboratory Markers for Critical COVID-19 on Admission. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2021, 2021, 1-8. | 0.7 | 7 |
| 269 | Compassionate use of anti-IL6 receptor antibodies in critically ill patients with acute respiratory distress syndrome due to SARS-COV-2. <i>Minerva Anestesiologica</i> , 2021, 87, 1080-1090. | 0.6 | 3 |
| 270 | Secondary haemophagocytic lymphohistiocytosis in hospitalised COVID-19 patients as indicated by a modified HScore is infrequent and high scores do not associate with increased mortality. <i>Clinical Medicine</i> , 2021, 21, e543-e547. | 0.8 | 3 |
| 271 | A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1706. | 1.5 | 9 |
| 272 | Ablation of PDE4B protects from <i>Pseudomonas aeruginosa</i> -induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia. <i>FASEB Journal</i> , 2021, 35, e21797. | 0.2 | 5 |
| 273 | Tocilizumab for coronavirus disease 2019 in pregnancy and lactation: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 51-57. | 2.8 | 18 |
| 274 | Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.. <i>The Lancet Regional Health Americas</i> , 2021, 2, 100062. | 1.5 | 33 |
| 275 | A review on the COVID-19: Facts and current situation. <i>NeuroPharmac Journal</i> , 0, , 180-191. | 0.1 | 3 |
| 276 | Bacterial Superinfection Pneumonia in Patients Mechanically Ventilated for COVID-19 Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 921-932. | 2.5 | 108 |
| 277 | SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 7457. | 1.3 | 11 |
| 278 | Phase III Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2353-2369. | 1.8 | 5 |
| 280 | Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. <i>Frontiers in Immunology</i> , 2021, 12, 709861. | 2.2 | 13 |
| 281 | Viral Infection, COVID-19 in Pregnancy and Lactating Women: What Is Known?. <i>Covid</i> , 2021, 1, 230-245. | 0.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 282 | Immune System Disequilibriumâ€”Neutrophils, Their Extracellular Traps, and COVID-19-Induced Sepsis. <i>Frontiers in Medicine</i> , 2021, 8, 711397. | 1.2 | 6 |
| 283 | Risk of Reactivation of Hepatitis B Virus (HBV) and Tuberculosis (TB) and Complications of Hepatitis C Virus (HCV) Following Tocilizumab Therapy: A Systematic Review to Inform Risk Assessment in the COVID-19 Era. <i>Frontiers in Medicine</i> , 2021, 8, 706482. | 1.2 | 23 |
| 284 | Management of infectious complications associated with coronavirus infection in severe patients admitted to ICU. <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 485-500. | 0.1 | 6 |
| 285 | Comparison of characteristics and ventilatory course between coronavirus disease 2019 and Middle East respiratory syndrome patients with acute respiratory distress syndrome. <i>Acute and Critical Care</i> , 2021, 36, 223-231. | 0.6 | 3 |
| 286 | Human Disease Phenotypes Associated with Loss and Gain of Function Mutations in STAT2: Viral Susceptibility and Type I Interferonopathy. <i>Journal of Clinical Immunology</i> , 2021, 41, 1446-1456. | 2.0 | 22 |
| 287 | The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia. <i>Trends in Cardiovascular Medicine</i> , 2022, 32, 1-9. | 2.3 | 31 |
| 288 | COVID-19 Immunobiology: Lessons Learned, New Questions Arise. <i>Frontiers in Immunology</i> , 2021, 12, 719023. | 2.2 | 28 |
| 289 | Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2455-2474. | 0.9 | 2 |
| 290 | IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 483. | 3.8 | 31 |
| 291 | Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan Î²-Coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 729622. | 1.8 | 11 |
| 292 | The janus-kinase inhibitor ruxolitinib in SARS-CoV-2 induced acute respiratory distress syndrome (ARDS). <i>Leukemia</i> , 2021, 35, 2917-2923. | 3.3 | 16 |
| 293 | A proteome-wide genetic investigation identifies several SARS-CoV-2-exploited host targets of clinical relevance. <i>ELife</i> , 2021, 10, . | 2.8 | 23 |
| 296 | COVID-19 Outbreak Management and Vaccination Strategy in The United States of America. <i>Epidemiologia</i> , 2021, 2, 426-453. | 1.1 | 1 |
| 297 | Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <i>Lancet, The</i> , 2021, 398, 843-855. | 6.3 | 204 |
| 298 | Interleukin-1RA Mitigates SARS-CoV-2â€”Induced Inflammatory Lung Vascular Leakage and Mortality in Humanized K18-hACE-2 Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2773-2785. | 1.1 | 20 |
| 299 | The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study. <i>Inflammation Research</i> , 2021, 70, 1233-1246. | 1.6 | 35 |
| 300 | Current status of therapeutic alternatives for COVID-19: A narrative review. <i>Infezioni in Medicina</i> , 2021, 29, 312-327. | 0.7 | 8 |
| 301 | Effect of mortality from COVIDâ€”19 on inpatient outcomes. <i>Journal of Medical Virology</i> , 2022, 94, 318-326. | 2.5 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 302 | Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically ill COVID-19 patients. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 316-329. | 0.4 | 14 |
| 303 | Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute Cardiovascular Care (ACVC), in collaboration with the European Heart Rhythm Association (FHRA). <i>Cardiovascular Research</i> , 2021, 117, 2705-2729. | 1.8 | 95 |
| 304 | Tocilizumab in SARS-COVID19 following postoperative laparoscopic transhiatal esophagectomy for the adenocarcinoma of esophagogastric tumor: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 86, 106343. | 0.2 | 1 |
| 305 | Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. <i>Psychoneuroendocrinology</i> , 2021, 131, 105295. | 1.3 | 83 |
| 306 | Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia: Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Investigative Medicine</i> , 2022, 70, 55-60. | 0.7 | 18 |
| 307 | Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1010-1020. | 5.2 | 54 |
| 308 | Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1752-1760. | 15.2 | 353 |
| 309 | Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1241. | 2.6 | 111 |
| 310 | Interferon β_2 , an enhancer of the innate immune response against SARS-CoV-2 infection. <i>Microbial Pathogenesis</i> , 2021, 158, 105105. | 1.3 | 6 |
| 311 | Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 515-523. | 4.5 | 6 |
| 312 | Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase. <i>Antiviral Research</i> , 2021, 193, 105142. | 1.9 | 19 |
| 313 | Rapid analysis of local data to inform off-label tocilizumab use early in the COVID-19 pandemic. <i>Healthcare</i> , 2021, 9, 100581. | 0.6 | 1 |
| 314 | Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0257376. | 1.1 | 6 |
| 315 | BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review. <i>Clinical Immunology</i> , 2021, 230, 108816. | 1.4 | 17 |
| 316 | Tocilizumab in COVID-19: The CerrahpaÅya-PREDICT score. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1329-1335. | 0.8 | 9 |
| 317 | Unraveling the role of liver sinusoidal endothelial cells in COVID-19 liver injury. <i>Journal of Hepatology</i> , 2021, 75, 503-505. | 1.8 | 5 |
| 318 | COVID-19 Critical Illness: A Data-Driven Review. <i>Annual Review of Medicine</i> , 2022, 73, 95-111. | 5.0 | 20 |
| 319 | Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls. <i>Rheumatology International</i> , 2022, 42, 457-467. | 1.5 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 320 | Cytokine inhibitors in COVID-19: looking back to move forward. <i>Minerva Anestesiologica</i> , 2021, 87, 848-850. | 0.6 | 0 |
| 321 | Adaptive Trials in Cardiology: Some Considerations and Examples. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1428-1437. | 0.8 | 2 |
| 322 | Real World Long-term Assessment of The Efficacy of Tocilizumab in Patients with COVID-19: Results From A Large De-identified Multicenter Electronic Health Record Dataset in the United States. <i>International Journal of Infectious Diseases</i> , 2021, 113, 148-154. | 1.5 | 2 |
| 323 | Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. <i>Frontiers in Immunology</i> , 2021, 12, 742941. | 2.2 | 81 |
| 324 | Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis. <i>Pharmacotherapy</i> , 2021, 41, 884-906. | 1.2 | 27 |
| 326 | Will Auranofin Become a Golden New Treatment Against COVID-19?. <i>Frontiers in Immunology</i> , 2021, 12, 683694. | 2.2 | 12 |
| 327 | Clinical trial research on COVID-19 in Germany – a systematic analysis. <i>F1000Research</i> , 0, 10, 913. | 0.8 | 5 |
| 328 | Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Public Health</i> , 2021, 9, 729559. | 1.3 | 27 |
| 329 | COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City. <i>Clinical Immunology</i> , 2021, 230, 108803. | 1.4 | 3 |
| 330 | Use of Tocilizumab May Avoid the Need of Invasive Ventilation. <i>Cureus</i> , 2021, 13, e17822. | 0.2 | 0 |
| 331 | Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1274-1285. | 2.5 | 121 |
| 333 | Clinical and laboratory factors associated with coronavirus disease 2019 (Covid-19): A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2021, 31, e2288. | 3.9 | 13 |
| 334 | Understanding the Potential Impact of Different Drug Properties on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Disease Burden: A Modelling Analysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e224-e233. | 2.9 | 10 |
| 335 | Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. <i>Pharmaceuticals</i> , 2021, 14, 955. | 1.7 | 12 |
| 336 | The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 734963. | 1.3 | 4 |
| 337 | Interleukin-6 in Critical Coronavirus Disease 2019, a Driver of Lung Inflammation of Systemic Origin? , 2021, 3, e0542. | | 1 |
| 338 | Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 708848. | 2.2 | 7 |
| 339 | Consensus statement and recommendations on the treatment of COVID-19: 2021 update. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 5-17. | 0.6 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 340 | Forty-fifth ASPEN Presidential Address: Research in a pandemic—Why, what, how?. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 1690-1702. | 1.3 | 1 |
| 341 | Emerging and Established Histological Techniques for the Analysis of Thrombosis in COVID-19 Lungs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 745906. | 1.1 | 1 |
| 342 | Management of COVID-19 Patients in the Emergency Department. <i>Journal of Personalized Medicine</i> , 2021, 11, 961. | 1.1 | 9 |
| 343 | Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 957-968. | 5.2 | 83 |
| 344 | COVID-19 infection after mRNA 1273 vaccine: review of the most frequently asked questions. <i>Infezioni in Medicina</i> , 2021, 29, 305-311. | 0.7 | 2 |
| 345 | Beyond the Extra Respiration of Phagocytosis: NADPH Oxidase 2 in Adaptive Immunity and Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 733918. | 2.2 | 20 |
| 347 | Scientific evidence in the COVID-19 treatment: A comprehensive review. <i>World Journal of Virology</i> , 2021, 10, 217-228. | 1.3 | 6 |
| 348 | Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1147-1149. | 13.9 | 56 |
| 349 | ERS International Congress 2020 virtual: highlights from the Respiratory Intensive Care Assembly. <i>ERJ Open Research</i> , 2021, 7, 00214-2021. | 1.1 | 0 |
| 350 | Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 244-259. | 0.8 | 2 |
| 351 | Response to Tocilizumab therapy and COVID-19. <i>Journal of Osteopathic Medicine</i> , 2021, 121, 867-868. | 0.4 | 0 |
| 352 | Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 4019. | 1.0 | 11 |
| 353 | Differences in the effectiveness of land consolidation projects in various countries and their causes: Examples of Poland and Turkey. <i>Land Use Policy</i> , 2021, 108, 105542. | 2.5 | 19 |
| 354 | Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study. <i>Scientific Reports</i> , 2021, 11, 17648. | 1.6 | 28 |
| 356 | Prompt Reduction in CRP, IL-6, IFN- γ , IP-10, and MCP-1 and a Relatively Low Basal Ratio of Ferritin/CRP Is Possibly Associated With the Efficacy of Tocilizumab Monotherapy in Severely to Critically Ill Patients With COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 734838. | 1.2 | 13 |
| 358 | Preface. <i>Critical Care Clinics</i> , 2021, 37, xiii-xv. | 1.0 | 0 |
| 359 | Immune response to COVID-19 in older adults. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1082-1089. | 0.3 | 13 |
| 360 | Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , 2021, 3, e690-e697. | 2.2 | 121 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 361 | Performance evaluation of a multinational data platform for critical care in Asia. Wellcome Open Research, 2021, 6, 251. | 0.9 | 6 |
| 362 | One year on: The impact of COVID-19 on clinical research. European Journal of Internal Medicine, 2021, 92, 24-27. | 1.0 | 2 |
| 363 | COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 667 Td (B Pharmacy Practice, 2023, 36, 407-417. | 0.5 | 27 |
| 364 | An update on the pathogenic role of IL-6 in rheumatic diseases. Cytokine, 2021, 146, 155645. | 1.4 | 11 |
| 365 | IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients. International Immunopharmacology, 2021, 99, 107998. | 1.7 | 4 |
| 366 | Role of IL-6 in the commitment of T cell subsets. Cytokine, 2021, 146, 155654. | 1.4 | 35 |
| 367 | Recent advances in management of COVID-19: A review. Biomedicine and Pharmacotherapy, 2021, 143, 112107. | 2.5 | 55 |
| 368 | Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study. Journal of Critical Care, 2021, 66, 44-51. | 1.0 | 5 |
| 369 | Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel. Clinical Infectious Diseases, 2022, 74, 1691-1695. | 2.9 | 16 |
| 370 | A New SARS-CoV-2 Variant Poorly Detected by RT-PCR on Nasopharyngeal Samples, with High Lethality. SSRN Electronic Journal, 0, , . | 0.4 | 2 |
| 371 | Clinical Profile and Outcomes of Confirmed COVID 19 at Manila Doctors Hospital. Asian Journal of Epidemiology, 2021, 14, 1-10. | 0.5 | 0 |
| 372 | Peripheral T cell lymphopenia in COVID-19: potential mechanisms and impact. Immunotherapy Advances, 2021, 1, . | 1.2 | 14 |
| 373 | Case Management of COVID-19 (Secondary Version). JMA Journal, 2021, 4, 191-197. | 0.6 | 18 |
| 375 | Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97. | 1.1 | 12 |
| 377 | Anti-Inflammatory Therapy of Infections. , 2022, , 791-797. | | 1 |
| 378 | Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia. Clinical Critical Care, 2021, , . | 0.0 | 0 |
| 379 | When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak. Frontiers in Immunology, 2021, 12, 692598. | 2.2 | 7 |
| 380 | Phenotyping in acute respiratory distress syndrome: state of the art and clinical implications. Current Opinion in Critical Care, 2022, 28, 1-8. | 1.6 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 381 | Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 231-247. | 1.6 | 9 |
| 382 | The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section. <i>Journal of Infection and Public Health</i> , 2022, 15, 142-151. | 1.9 | 10 |
| 383 | Efficacy and Safety of Sarilumab in patients with COVID19 Pneumonia: A Randomized, Phase III Clinical Trial (SARTRE Study). <i>Infectious Diseases and Therapy</i> , 2021, 10, 2735-2748. | 1.8 | 17 |
| 384 | The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?. <i>Intensive Care Medicine</i> , 2021, 47, 1315-1318. | 3.9 | 6 |
| 385 | Changes in the Epidemiology of Ventilator-Associated Events over the Course of the Covid-19 Pandemic. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-10. | 1.0 | 2 |
| 386 | Comprehensive Review of Cardiovascular Complications of Coronavirus Disease 2019 and Beneficial Treatments. <i>Cardiology in Review</i> , 2022, 30, 145-157. | 0.6 | 11 |
| 387 | Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry. <i>European Journal of Medical Research</i> , 2021, 26, 117. | 0.9 | 18 |
| 389 | Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis. <i>Respirology</i> , 2021, 26, 1027-1040. | 1.3 | 22 |
| 390 | Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. <i>Seminars in Immunology</i> , 2021, 55, 101508. | 2.7 | 37 |
| 391 | Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials. <i>Annals of Intensive Care</i> , 2021, 11, 152. | 2.2 | 14 |
| 392 | A new SARS-CoV-2 variant with high lethality poorly detected by RT-PCR on nasopharyngeal samples: an observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 298.e9-298.e15. | 2.8 | 13 |
| 393 | Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690. | 3.8 | 169 |
| 394 | Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2132. | 1.5 | 29 |
| 395 | Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ, The</i> , 2021, 375, n2400. | 3.0 | 250 |
| 396 | Standardized Extract of Asparagus officinalis Stem Attenuates SARS-CoV-2 Spike Protein-Induced IL-6 and IL-1 β Production by Suppressing p44/42 MAPK and Akt Phosphorylation in Murine Primary Macrophages. <i>Molecules</i> , 2021, 26, 6189. | 1.7 | 14 |
| 397 | Traitements systématiques et risque infectieux dans le contexte de pandémie COVID-19. <i>Annales De Dermatologie Et De Vénéréologie, FMC</i> , 2021, 1, 5S6-5S12. | 0.0 | 0 |
| 398 | One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 95, 5-6. | 1.0 | 7 |
| 399 | The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies. <i>Journal of Clinical Medicine</i> , 2021, 10, 4935. | 1.0 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 400 | Mapping Pulmonary and Systemic Inflammation in Preschool Aged Children With Cystic Fibrosis. <i>Frontiers in Immunology</i> , 2021, 12, 733217. | 2.2 | 8 |
| 401 | Rapid Detection and Inhibition of SARS-CoV-2 Spike Mutation-Mediated Microthrombosis. <i>Advanced Science</i> , 2021, 8, e2103266. | 5.6 | 11 |
| 402 | Harnessing autophagy to fight SARS-CoV-2: An update in view of recent drug development efforts. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 155-160. | 1.2 | 5 |
| 403 | Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494. | 5.0 | 11 |
| 404 | Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections. <i>F1000Research</i> , 0, 10, 536. | 0.8 | 10 |
| 405 | Complications of Critical COVID-19. <i>Chest</i> , 2022, 161, 989-998. | 0.4 | 14 |
| 406 | Clinical research methodology process: what is changing with COVID-19?. <i>European Heart Journal Supplements</i> , 2021, 23, E161-E167. | 0.0 | 1 |
| 407 | Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 743582. | 1.6 | 14 |
| 408 | Host genetic factors determining COVID-19 susceptibility and severity. <i>EBioMedicine</i> , 2021, 72, 103629. | 2.7 | 126 |
| 409 | The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers. <i>Journal of General Internal Medicine</i> , 2021, , 1. | 1.3 | 7 |
| 410 | Lower versus higher oxygenation targets in critically ill patients with severe hypoxaemia: secondary Bayesian analysis to explore heterogeneous treatment effects in the Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU) trial. <i>British Journal of Anaesthesia</i> , 2022, 128, 55-64. | 1.5 | 16 |
| 411 | Hemoperfusion and blood purification strategies in patients with COVID-19: A systematic review. <i>Artificial Organs</i> , 2021, 45, 1466-1476. | 1.0 | 20 |
| 412 | COVID-19 survivors with calcineurin-inhibitors-treated rheumatoid arthritis. <i>Modern Rheumatology Case Reports</i> , 2021, , . | 0.3 | 1 |
| 413 | Role of neutrophils, platelets, and extracellular vesicles and their interactions in COVID-19-associated thrombopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 17-31. | 1.9 | 45 |
| 414 | Anti-IL-6 receptor antibodies in SARS-Cov-2 infection: perhaps, but certainly not for all. <i>Minerva Anestesiologica</i> , 2021, 87, 1064-1066. | 0.6 | 0 |
| 415 | Glucocorticoid Dose in COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1801. | 3.8 | 8 |
| 416 | Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*. <i>Critical Care Medicine</i> , 2022, 50, 398-409. | 0.4 | 27 |
| 417 | Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 585-609. | 2.0 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 418 | Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. <i>Intensive Care Medicine</i> , 2021, 47, 1258-1270. | 3.9 | 88 |
| 419 | COVID-19 Advanced Care. <i>Journal of Personalized Medicine</i> , 2021, 11, 1082. | 1.1 | 1 |
| 420 | Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1807. | 3.8 | 174 |
| 421 | 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 34-40. | 0.5 | 26 |
| 422 | Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial. <i>EClinicalMedicine</i> , 2021, 41, 101167. | 3.2 | 22 |
| 423 | Myeloid cells in COVID-19 microenvironment. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 372. | 7.1 | 14 |
| 425 | COVID-19-related Acute Respiratory Distress Syndrome Subphenotypes and Differential Response to Corticosteroids: Time for More Precision?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1241-1243. | 2.5 | 6 |
| 426 | Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases. <i>Cardiology Journal</i> , 2021, 28, 979-982. | 0.5 | 0 |
| 427 | Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data. <i>Infectious Diseases and Therapy</i> , 2021, , 1. | 1.8 | 6 |
| 428 | Bioelectric impedance body composition and phase angle in relation to 90-day adverse outcome in hospitalized COVID-19 ward and ICU patients: The prospective BIAC-19 study. <i>Clinical Nutrition ESPEN</i> , 2021, 46, 185-192. | 0.5 | 21 |
| 429 | Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1955-1963. | 1.1 | 22 |
| 430 | Immunomodulatory therapies for the treatment of SARS-CoV-2 infection: an update of the systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001899. | 1.8 | 8 |
| 431 | Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 1067-1073. | 2.5 | 12 |
| 432 | Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. , 2022, 233, 108027. | | 2 |
| 433 | Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. <i>Internal and Emergency Medicine</i> , 2022, 17, 329-338. | 1.0 | 13 |
| 434 | Low frequency of community-acquired bacterial co-infection in patients hospitalized for COVID-19 based on clinical, radiological and microbiological criteria: a retrospective cohort study. <i>Antimicrobial Resistance and Infection Control</i> , 2021, 10, 155. | 1.5 | 17 |
| 435 | Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 1427-1438. | 5.2 | 86 |
| 436 | Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 765330. | 2.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 437 | COVID-19 susceptibility and outcomes among patients with neuromyelitis optica spectrum disorder (NMOSD): A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103359. | 0.9 | 18 |
| 438 | COVID 19 and the risk of gastro-intestinal perforation: A case series and literature review. <i>Journal of Critical Care</i> , 2022, 67, 100-103. | 1.0 | 14 |
| 439 | Complex Pathophysiological Mechanisms and the Propose of the Three-Dimensional Schedule For Future COVID-19 Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 716940. | 2.2 | 1 |
| 440 | Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. <i>BMJ, The</i> , 2021, 375, e068060. | 3.0 | 52 |
| 441 | Hostâ€modifying drugs against <scp>COVID</scp>â€19: some successes, but not yet the breakthrough. <i>Environmental Microbiology</i> , 2021, 23, 7257-7270. | 1.8 | 0 |
| 442 | Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081. | 1.8 | 21 |
| 443 | Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524. | 2.7 | 9 |
| 444 | Signals were broadly positive for months, but never definitive: the tocilizumab story. <i>Clinical Microbiology and Infection</i> , 2021, , . | 2.8 | 1 |
| 445 | Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. , 2021, 3, e0566. | | 5 |
| 446 | Prevalence and Clinical Implications of COVID-19 Myocarditis. <i>Cardiac Electrophysiology Clinics</i> , 2022, 14, 53-62. | 0.7 | 16 |
| 447 | COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454. | 3.3 | 57 |
| 448 | Complex immune deregulation in severe COVID-19: More than a mechanism of pathogenesis. <i>EBioMedicine</i> , 2021, 73, 103673. | 2.7 | 6 |
| 450 | Microencapsulated Wharton Jelly-derived adult mesenchymal stem cells as a potential new therapeutic tool for patients with COVID-19 disease: an in vitro study. <i>American Journal of Stem Cells</i> , 2021, 10, 36-52. | 0.4 | 0 |
| 451 | Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112419. | 2.5 | 34 |
| 452 | A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. <i>Purinergic Signalling</i> , 2022, 18, 13-59. | 1.1 | 20 |
| 453 | What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 281-288. | 1.3 | 8 |
| 454 | Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study. <i>RMD Open</i> , 2021, 7, e001906. | 1.8 | 4 |
| 455 | Cardiovascular Effects of Chocolate and Wineâ€Narrative Review. <i>Nutrients</i> , 2021, 13, 4269. | 1.7 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 456 | Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorb® Basics, Indications and Perspectives – A Scoping Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12786. | 1.8 | 21 |
| 457 | Dismal Survival in COVID-19 Patients Requiring ECMO as Rescue Therapy after Corticosteroid Failure. <i>Journal of Personalized Medicine</i> , 2021, 11, 1238. | 1.1 | 2 |
| 458 | SARS-CoV-2 Spike Protein-Induced Interleukin 6 Signaling Is Blocked by a Plant-Produced Anti-Interleukin 6 Receptor Monoclonal Antibody. <i>Vaccines</i> , 2021, 9, 1365. | 2.1 | 14 |
| 459 | A call for caution in the immunocompromised: COVID-19 associated with mortality in a vaccinated lung transplant recipient. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab557. | 0.4 | 2 |
| 460 | Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2021, 29, 449-467. | 0.9 | 7 |
| 461 | COVID-19 associated infections in the ICU setting: A retrospective analysis in a tertiary-care hospital. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2023, 41, 278-283. | 0.3 | 14 |
| 462 | Tocilizumab in severe COVID-19: A promise fulfilled. <i>European Journal of Internal Medicine</i> , 2022, 95, 38-39. | 1.0 | 5 |
| 464 | IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study. <i>Cardiology Journal</i> , 2022, 29, 140-147. | 0.5 | 9 |
| 466 | Outcomes Associated with Tocilizumab with or without Corticosteroid versus Dexamethasone for Treatment of Patients with Severe to Critical COVID-19 pneumonia. <i>Journal of Infection and Public Health</i> , 2021, 15, 36-41. | 1.9 | 6 |
| 467 | ESCMID COVID-19 living guidelines: drug treatment and clinical management. <i>Clinical Microbiology and Infection</i> , 2022, 28, 222-238. | 2.8 | 103 |
| 468 | Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. <i>Respiratory Research</i> , 2021, 22, 304. | 1.4 | 7 |
| 469 | COVID-19 in Children. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 1-14. | 1.9 | 10 |
| 470 | Efficacy and Safety of Immunomodulators in Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Infectious Diseases and Therapy</i> , 2022, 11, 231-248. | 1.8 | 15 |
| 471 | Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <i>World Journal of Pharmacology</i> , 2021, 10, 1-32. | 1.3 | 1 |
| 472 | Retrospective cohort study to evaluate medication use in patients hospitalised with COVID-19 in Scotland: protocol for a national observational study. <i>BMJ Open</i> , 2021, 11, e054861. | 0.8 | 3 |
| 473 | Tocilizumab in critically ill COVID-19 patients: An observational study. <i>International Immunopharmacology</i> , 2022, 102, 108384. | 1.7 | 9 |
| 474 | Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome. <i>Acta Microbiologica Et Immunologica Hungarica</i> , 2021, 68, 240-255. | 0.4 | 2 |
| 475 | Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13009. | 1.8 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 476 | The paradox of immunosuppressants and COVID-19. <i>European Respiratory Journal</i> , 2022, 59, 2102828. | 3.1 | 8 |
| 477 | Phenotypes, Lung Microbiota and Cytokine Responses in Pneumonia After Hematopoietic Stem Cell Transplantation. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6055-6065. | 1.6 | 1 |
| 478 | Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial. <i>Intensive Care Medicine</i> , 2022, 48, 36-44. | 3.9 | 22 |
| 479 | Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients. <i>Journal of Medical Virology</i> , 2022, 94, 1540-1549. | 2.5 | 13 |
| 480 | Covid-19: surging demand for some arthritis drugs. <i>BMJ</i> , The, 0, , n2700. | 3.0 | 1 |
| 482 | Predictors and microbiology of respiratory and bloodstream bacterial infection in patients with COVID-19: living rapid review update and meta-regression. <i>Clinical Microbiology and Infection</i> , 2022, 28, 491-501. | 2.8 | 45 |
| 483 | Early Fall in C-Reactive Protein (CRP) Level Predicts Response to Tocilizumab in Rapidly Progressing COVID-19: Experience in a Single-Arm Pakistani Center. <i>Cureus</i> , 2021, 13, e20031. | 0.2 | 3 |
| 484 | Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 324-329. | 2.5 | 16 |
| 485 | Dexamethasone 12Âmg versus 6Âmg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. <i>Intensive Care Medicine</i> , 2022, 48, 45-55. | 3.9 | 70 |
| 486 | Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER). <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 758-766. | 1.3 | 15 |
| 487 | Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5366. | 1.0 | 4 |
| 488 | Treatments for COVID-19: Lessons from 2020 and new therapeutic options. <i>Current Opinion in Pharmacology</i> , 2022, 62, 43-59. | 1.7 | 23 |
| 489 | Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 158-166. | 5.2 | 37 |
| 490 | Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629. | 4.7 | 32 |
| 491 | Single-dose tocilizumab blunts systemic inflammation in severe COVID-19 patients. <i>Journal of Critical Care</i> , 2021, , . | 1.0 | 0 |
| 493 | Pathogenesis of Respiratory Viral and Fungal Coinfections. <i>Clinical Microbiology Reviews</i> , 2022, 35, e0009421. | 5.7 | 64 |
| 494 | Promises and challenges of personalized medicine to guide ARDS therapy. <i>Critical Care</i> , 2021, 25, 404. | 2.5 | 35 |
| 495 | It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103426. | 0.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 496 | Post-mortem lung tissue: the fossil record of the pathophysiology and immunopathology of severe COVID-19. <i>Lancet Respiratory Medicine</i> , 2022, 10, 95-106. | 5.2 | 34 |
| 497 | Reduction of venous thromboembolic events in COVID-19 patients: Which role for IL-6 antagonists?. <i>Thrombosis Research</i> , 2021, 208, 170-172. | 0.8 | 1 |
| 498 | ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically Ill COVID-19 Patients. <i>Journal of Innate Immunity</i> , 2022, 14, 218-228. | 1.8 | 21 |
| 499 | Therapeutic implications of ongoing alveolar viral replication in COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e135-e144. | 2.2 | 17 |
| 500 | Randomised clinical trials in critical care: past, present and future. <i>Intensive Care Medicine</i> , 2022, 48, 164-178. | 3.9 | 46 |
| 501 | Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19). <i>Drugs and Aging</i> , 2021, 38, 1067-1074. | 1.3 | 11 |
| 502 | A Tale of Two Waves: Changes in the Use of Noninvasive Ventilation and Prone Positioning in Critical Care Management of Coronavirus Disease 2019. , 2021, 3, e0587. | | 6 |
| 503 | Stimulating severe COVID-19: the potential role of GM-CSF antagonism. <i>Lancet Respiratory Medicine</i> , 2022, 10, 223-224. | 5.2 | 10 |
| 504 | Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). <i>Acute Medicine & Surgery</i> , 2021, 8, e706. | 0.5 | 16 |
| 505 | The immunology and immunotherapy for COVID-19. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e24. | 1.6 | 2 |
| 507 | Cardiovascular Burden of COVID-19 and the Post-Covid Era. , 2021, 1, 1-10. | | 0 |
| 508 | Evaluation of I-TAC as a potential early plasma marker to differentiate between critical and non-critical COVID-19. <i>Cell Stress</i> , 2021, 6, 6-16. | 1.4 | 3 |
| 509 | Comparing the efficacy of tocilizumab with corticosteroid therapy in treating COVID-19 patients: a systematic review and meta-analysis. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2022, 30, 211-228. | 0.9 | 12 |
| 510 | A review of COVID-19 therapeutics in pregnancy and lactation. <i>Obstetric Medicine</i> , 2022, 15, 225-232. | 0.5 | 13 |
| 511 | Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 17-32. | 2.9 | 10 |
| 512 | Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 101702. | 0.3 | 0 |
| 513 | Experience of Rwanda on COVID-19 Case Management: From Uncertainties to the Era of Neutralizing Monoclonal Antibodies. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1023. | 1.2 | 3 |
| 514 | Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. <i>Nature Communications</i> , 2022, 13, 440. | 5.8 | 100 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 515 | Effects of IFIH1 rs1990760 variants on systemic inflammation and outcome in critically ill COVID-19 patients in an observational translational study. <i>ELife</i> , 2022, 11, . | 2.8 | 16 |
| 516 | Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies. <i>Frontiers in Immunology</i> , 2021, 12, 781100. | 2.2 | 19 |
| 517 | Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations. <i>Cells</i> , 2022, 11, 306. | 1.8 | 15 |
| 518 | Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6. <i>Viral Immunology</i> , 2022, 35, 60-70. | 0.6 | 6 |
| 519 | Therapeutic role of immunomodulators during the COVID-19 pandemic – a narrative review. <i>Postgraduate Medicine</i> , 2022, 134, 160-179. | 0.9 | 9 |
| 520 | A learning health system approach to the COVID-19 pandemic: System-wide changes in clinical practice and 30-day mortality among hospitalized patients. <i>Learning Health Systems</i> , 2022, 6, . | 1.1 | 7 |
| 521 | Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402. | 1.6 | 20 |
| 523 | Innate immunological pathways in COVID-19 pathogenesis. <i>Science Immunology</i> , 2022, 7, eabm5505. | 5.6 | 101 |
| 524 | Strategies for drug repurposing against coronavirus targets. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100072. | 1.7 | 11 |
| 525 | First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy. <i>BMJ Open</i> , 2022, 12, e054069. | 0.8 | 13 |
| 526 | Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling. <i>EBioMedicine</i> , 2022, 75, 103809. | 2.7 | 9 |
| 527 | Pulmonary Aspects of COVID-19. <i>Annual Review of Medicine</i> , 2022, 73, 81-93. | 5.0 | 8 |
| 528 | Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. <i>Medicina (Lithuania)</i> , 2022, 58, 144. | 0.8 | 126 |
| 529 | Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. <i>Inflammopharmacology</i> , 2022, 30, 23-49. | 1.9 | 8 |
| 530 | Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications. <i>World Journal of Clinical Cases</i> , 2022, 10, 762-776. | 0.3 | 12 |
| 531 | COVID-19 in the Critically Ill Pregnant Patient. <i>Critical Care Clinics</i> , 2022, , . | 1.0 | 5 |
| 532 | Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet, The</i> , 2022, 399, 530-540. | 6.3 | 48 |
| 533 | Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. <i>Lancet Rheumatology, The</i> , 2022, 4, e24-e32. | 2.2 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 534 | The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. <i>Lancet Microbe, The</i> , 2022, 3, e543-e552. | 3.4 | 255 |
| 535 | Associations between body composition, fat distribution and metabolic consequences of excess adiposity with severe COVID-19 outcomes: observational study and Mendelian randomisation analysis. <i>International Journal of Obesity</i> , 2022, 46, 943-950. | 1.6 | 24 |
| 536 | COVID-19 and Acute Kidney Injury. <i>Critical Care Clinics</i> , 2022, 38, 473-489. | 1.0 | 21 |
| 537 | The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India. , 2022, 13, 24. | | 9 |
| 538 | Impact of the COVID-19 pandemic on uveitis patient care. <i>British Journal of Ophthalmology</i> , 2023, 107, 790-794. | 2.1 | 5 |
| 539 | Predictive Performance and Clinical Application of COV50, A Urinary Proteomic Biomarker in Early COVID-19 Infection: A Cohort Study. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 540 | SARS-CoV-2 infections in patients with autoimmune blistering disorders: A case series and retrospective analysis. <i>JAAD International</i> , 2022, 7, 38-43. | 1.1 | 7 |
| 541 | Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis. <i>Aging</i> , 2022, 14, 557-571. | 1.4 | 9 |
| 542 | Inflammation and Mortality in COVID-19 Hospitalized Patients With and Without Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, , . | 1.8 | 8 |
| 543 | Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 804250. | 1.6 | 17 |
| 544 | Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. <i>Journal of Biomedical Science</i> , 2022, 29, 1. | 2.6 | 144 |
| 545 | How common is ventilator-associated pneumonia after coronavirus disease 2019?. <i>Current Opinion in Infectious Diseases</i> , 2022, Publish Ahead of Print, . | 1.3 | 6 |
| 546 | Effect of Tocilizumab Treatment on Patients with Coronavirus Disease 2019 and Bacteremia: A Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 533-541. | 1.8 | 3 |
| 547 | Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis. <i>Innate Immunity</i> , 2022, 28, 3-10. | 1.1 | 1 |
| 548 | A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50. | 15.2 | 206 |
| 549 | Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 546. | 3.8 | 229 |
| 550 | Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis. <i>PLoS ONE</i> , 2022, 17, e0262908. | 1.1 | 2 |
| 551 | Proactive vs Reactive Machine Learning in Health Care. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 623. | 3.8 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 552 | Low levels of CIITA and high levels of SOCS1 predict COVID-19 disease severity in children and adults. <i>IScience</i> , 2022, 25, 103595. | 1.9 | 2 |
| 553 | IL-6 Revisited: From Rheumatoid Arthritis to CAR T Cell Therapy and COVID-19. <i>Annual Review of Immunology</i> , 2022, 40, 323-348. | 9.5 | 50 |
| 554 | Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 569-578. | 1.5 | 3 |
| 555 | Airway recommendations for perioperative patients during the COVID-19 pandemic: a scoping review. <i>Canadian Journal of Anaesthesia</i> , 2022, 69, 644-657. | 0.7 | 3 |
| 556 | COVID-19 Pathogenesis and Clinical Manifestations. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 231-249. | 1.9 | 21 |
| 557 | Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. <i>Inflammation Research</i> , 2022, 71, 293-307. | 1.6 | 29 |
| 558 | COVID-19 in the Immunocompromised Host, Including People with Human Immunodeficiency Virus. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 397-421. | 1.9 | 7 |
| 559 | Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy. <i>Chemical Reviews</i> , 2022, 122, 5977-6039. | 23.0 | 92 |
| 560 | Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 3.9 | 15 |
| 561 | Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences. , 2022, 235, 108121. | | 20 |
| 562 | Innate immunity: the first line of defense against SARS-CoV-2. <i>Nature Immunology</i> , 2022, 23, 165-176. | 7.0 | 303 |
| 563 | Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication. <i>Biochemical Pharmacology</i> , 2022, 197, 114909. | 2.0 | 19 |
| 564 | A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. <i>Cell</i> , 2022, 185, 916-938.e58. | 13.5 | 164 |
| 565 | Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. <i>European Respiratory Journal</i> , 2022, 60, 2102523. | 3.1 | 31 |
| 566 | Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. <i>Annals of Medicine</i> , 2022, 54, 524-540. | 1.5 | 225 |
| 567 | Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>Monaldi Archives for Chest Disease</i> , 2022, , . | 0.3 | 4 |
| 568 | Pharmacologic Treatment and Management of Coronavirus Disease 2019. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 349-364. | 1.9 | 2 |
| 569 | Community-Acquired Pneumonia in Canada During Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac043. | 0.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 570 | American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3. <i>Arthritis and Rheumatology</i> , 2022, 74, . | 2.9 | 146 |
| 571 | Reactivation of Herpes Simplex Virus Type 1 (HSV-1) Detected on Bronchoalveolar Lavage Fluid (BALF) Samples in Critically Ill COVID-19 Patients Undergoing Invasive Mechanical Ventilation: Preliminary Results from Two Italian Centers. <i>Microorganisms</i> , 2022, 10, 362. | 1.6 | 14 |
| 572 | COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments. <i>Acta Haematologica</i> , 2022, 145, 244-256. | 0.7 | 7 |
| 573 | Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series. <i>AIDS Research and Therapy</i> , 2022, 19, 6. | 0.7 | 4 |
| 574 | Lessons from the COVID-19 pandemic. <i>Therapie</i> , 2021, 77, 3-3. | 0.6 | 1 |
| 575 | Metabolic reprogramming shapes neutrophil functions in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 484-502. | 1.6 | 34 |
| 576 | Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?. <i>Current Infectious Disease Reports</i> , 2021, 23, 28. | 1.3 | 5 |
| 577 | Development of a repeated-measures predictive model and clinical risk score for mortality in ventilated COVID-19 patients. <i>Canadian Journal of Anaesthesia</i> , 2022, 69, 343-352. | 0.7 | 4 |
| 578 | Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 237-246. | 5.2 | 50 |
| 579 | The state of complement in COVID-19. <i>Nature Reviews Immunology</i> , 2022, 22, 77-84. | 10.6 | 159 |
| 580 | The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline. <i>European Respiratory Review</i> , 2021, 30, 210171. | 3.0 | 20 |
| 581 | Pharmacological treatment of COVID-19: an opinion paper. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 115-130. | 0.5 | 47 |
| 582 | Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review. <i>Infezioni in Medicina</i> , 2021, 29, 495-503. | 0.7 | 12 |
| 583 | COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients. <i>Expert Reviews in Molecular Medicine</i> , 2022, 24, e13. | 1.6 | 12 |
| 584 | Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. <i>Alexander Saltanov Intensive Care Herald</i> , 2022, , 5-140. | 0.2 | 7 |
| 585 | Artificial Intelligence in Critical Care Medicine. Annual Update in Intensive Care and Emergency Medicine, 2022, , 353-367. | 0.1 | 2 |
| 586 | COVID-19 and lung involvement. <i>Handbook of Systemic Autoimmune Diseases</i> , 2022, , 189-211. | 0.1 | 0 |
| 587 | Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib) a biological or synthetic) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i> 68, 3-8. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 588 | COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204. | 3.5 | 105 |
| 589 | COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study. <i>Leukemia and Lymphoma</i> , 2022, 63, 1607-1616. | 0.6 | 4 |
| 590 | SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275. | 1.2 | 9 |
| 591 | A Retrospective Observational Cohort Study on the Efficacy and Safety of Methylprednisolone Pulse Therapy for COVID-19 Pneumonia. <i>Covid</i> , 2022, 2, 244-253. | 0.7 | 2 |
| 592 | Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. , 2022, 1, e000036. | | 13 |
| 593 | Successful high flow nasal cannula therapy for severe COVID-19 pneumonia is associated with tocilizumab use. <i>Infectious Diseases Now</i> , 2022, , . | 0.7 | 4 |
| 595 | Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop. <i>Vaccine</i> , 2022, 40, 3484-3489. | 1.7 | 6 |
| 596 | Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review. <i>Geriatrics (Switzerland)</i> , 2022, 7, 22. | 0.6 | 2 |
| 597 | Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids. <i>JAMA Network Open</i> , 2022, 5, e220548. | 2.8 | 16 |
| 598 | Kidney Injury in COVID-19: Epidemiology, Molecular Mechanisms and Potential Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2242. | 1.8 | 17 |
| 599 | Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0210721. | 1.4 | 22 |
| 600 | COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. <i>Kidney International</i> , 2022, 101, 883-894. | 2.6 | 82 |
| 601 | Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial. <i>Critical Care</i> , 2022, 26, 48. | 2.5 | 62 |
| 604 | A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 <i>trans</i>-Signaling and Cellular Infection with SARS-CoV-2. <i>Journal of Virology</i> , 2022, 96, JVI0162221. | 1.5 | 5 |
| 605 | Tocilizumab and COVID-19: Timing of Administration and Efficacy. <i>Frontiers in Pharmacology</i> , 2022, 13, 825749. | 1.6 | 27 |
| 606 | Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease. <i>Medicina Intensiva (English Edition)</i> , 2022, , . | 0.1 | 1 |
| 607 | Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. <i>PLoS ONE</i> , 2022, 17, e0263591. | 1.1 | 10 |
| 608 | The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri [®]) in subjects with acute respiratory distress syndrome induced by COVID-19. <i>Trials</i> , 2022, 23, 158. | 0.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 610 | Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. <i>Frontiers in Medicine</i> , 2022, 9, 849222. | 1.2 | 2 |
| 611 | Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. <i>Nature Communications</i> , 2022, 13, 915. | 5.8 | 32 |
| 612 | Ofelecin i mi Vlaptinâ€™ Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. <i>Medicina (Lithuania)</i> , 2022, 58, 309. | 0.8 | 4 |
| 613 | MAP2K2 Delays Recovery in Murine Models of Acute Lung Injury and Associates with ARDS Outcome. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, , . | 1.4 | 1 |
| 614 | Tocilizumab: A Role for Biomarker-Directed Therapy?*. <i>Critical Care Medicine</i> , 2022, 50, 510-513. | 0.4 | 0 |
| 615 | Enigma of categorizing COVID-19-related lung parenchymal diseases and management experience with follow-up outcomes in Qatar: a case series. <i>Qatar Medical Journal</i> , 2022, 2022, 2. | 0.2 | 0 |
| 616 | Molecular Insights of SARS-CoV-2 Antivirals Administration: A Balance between Safety Profiles and Impact on Cardiovascular Phenotypes. <i>Biomedicines</i> , 2022, 10, 437. | 1.4 | 5 |
| 617 | The Current Role for Biologic Medications in the Treatment of Pediatric COVID-19 and MIS-C. <i>Pediatric Annals</i> , 2022, 51, e57-e62. | 0.3 | 0 |
| 618 | COVID-19 ARDS: One Pathogen, Multiple Phenotypes. <i>Critical Care Clinics</i> , 2022, , . | 1.0 | 6 |
| 619 | Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling. <i>Frontiers in Immunology</i> , 2022, 13, 795315. | 2.2 | 35 |
| 620 | The Impact of Tocilizumab on Radiological Changes Assessed by Quantitative Chest CT in Severe COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 1247. | 1.0 | 9 |
| 621 | Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial. <i>Frontiers in Medicine</i> , 2022, 9, 819621. | 1.2 | 4 |
| 622 | Review of Anti-inflammatory and Anti-viral therapeutics for hospitalized patients infected with SARS-CoV-2. <i>Critical Care Clinics</i> , 2022, , . | 1.0 | 3 |
| 623 | CD4⁺T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-Î±/Tumor Necrosis Factor Receptor 1â€™-Dependent. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1403-1418. | 2.5 | 21 |
| 625 | Artificial Intelligence in Critical Care Medicine. <i>Critical Care</i> , 2022, 26, 75. | 2.5 | 41 |
| 626 | Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 11, 100228. | 1.5 | 2 |
| 627 | Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. <i>Blood</i> , 2022, 140, 208-221. | 0.6 | 13 |
| 628 | How far are we from predicting multiâ€™drug interactions during treatment for COVIDâ€™19 infection?. <i>British Journal of Pharmacology</i> , 2022, 179, 3831-3838. | 2.7 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 629 | Vaginal delivery after improvement in COVID-19 by monoclonal antibody treatment: A case report and literature review. <i>Journal of Infection and Chemotherapy</i> , 2022, , . | 0.8 | 2 |
| 630 | COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response. <i>Acta Haematologica</i> , 2022, 145, 297-309. | 0.7 | 7 |
| 631 | æ-°ăžã,³ăfăfŠă, ă,ăf«ă,¹æ,,ÿæÿ“ç-†ă•æ²»ç™,æ^ ç•¥ă•ăf-ă,ăfăf³ă«ăă,ăđă€•. <i>Nihon Jibi Inkoka Tokeibu Geka Gakkai Kaito</i> , 2022, , . | | |
| 632 | Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications. <i>EBioMedicine</i> , 2022, 77, 103894. | 2.7 | 12 |
| 633 | Clinical Evidence Generation During a Pandemic. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 151-156. | 1.0 | 2 |
| 634 | Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 611-621. | 4.6 | 22 |
| 635 | Post-COVID-19 Pulmonary Fibrosis. <i>Cureus</i> , 2022, 14, e22770. | 0.2 | 17 |
| 636 | Pediatric Device Trials are the Ideal way to Bring Devices to Market. <i>World Journal for Pediatric & Congenital Heart Surgery</i> , 2022, 13, 231-234. | 0.3 | 1 |
| 637 | Flipped Inflammatory Time and the Role of Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2: Optimizing Tocilizumab Against Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, , . | 1.9 | 0 |
| 638 | Niclosamideâ€”A promising treatment for COVIDâ€”19. <i>British Journal of Pharmacology</i> , 2022, 179, 3250-3267. | 2.7 | 31 |
| 639 | Sickle Cell Disease and COVID-19 Infection: Importance of COVID-19 Testing and Approach to Management. <i>Cureus</i> , 2022, 14, e23604. | 0.2 | 0 |
| 640 | Effectiveness of Tocilizumab in hospitalized moderate-to-severe COVID-19 patients: a real life study. <i>Panminerva Medica</i> , 2022, , . | 0.2 | 1 |
| 641 | Evaluation of aerosolized epoprostenol for hypoxemia in non-intubated patients with coronavirus disease 2019. <i>Hospital Practice (1995)</i> , 2022, 50, 118-123. | 0.5 | 5 |
| 642 | Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e380-e388. | 2.9 | 27 |
| 643 | Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry. <i>Internal and Emergency Medicine</i> , 2022, 17, 1115-1127. | 1.0 | 4 |
| 644 | Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORMâ€”a prospective, randomized, single-centre, open-label study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 844-851. | 2.8 | 25 |
| 645 | Drug dosing in hospitalized obese patients with COVID-19. <i>Critical Care</i> , 2022, 26, 60. | 2.5 | 3 |
| 648 | Treatment of severe covid-19 with interleukin 6 receptor inhibition. , 2022, 1, e000144. | | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 649 | Neuroimmunology and Neurological Manifestations of COVID-19. , 0, , . | | 0 |
| 650 | A Multicenter Evaluation of the Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19. , 2022, 4, e0662. | | 23 |
| 651 | Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients. IScience, 2022, 25, 104075. | 1.9 | 5 |
| 652 | Effectiveness of tocilizumab in the treatment of hospitalized adults COVID-19. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overloc | 0.4 | 12 |
| 653 | Energy requirements for critically ill patients with COVID-19. Nutrition in Clinical Practice, 2022, 37, 594-604. | 1.1 | 6 |
| 654 | A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. Pathogens, 2022, 11, 368. | 1.2 | 23 |
| 657 | COVID-19 FAQs in Pediatric Cardiac Surgery: 2022 Perspective and Updates. World Journal for Pediatric & Congenital Heart Surgery, 2022, , 215013512210859. | 0.3 | 1 |
| 658 | Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis. Emerging Microbes and Infections, 2022, 11, 1154-1165. | 3.0 | 25 |
| 659 | Management of hepatitis B virus reactivation due to treatment of COVID-19. Hepatology International, 2022, 16, 257-268. | 1.9 | 17 |
| 660 | Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial. British Journal of General Practice, 2022, 72, e446-e455. | 0.7 | 19 |
| 661 | CD24Fc: an emerging COVID-19 therapy. Lancet Infectious Diseases, The, 2022, 22, 565-567. | 4.6 | 4 |
| 662 | Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection. Journal of International Medical Research, 2022, 50, 030006052210828. | 0.4 | 4 |
| 663 | Development of a clinical risk score to predict death in patients with COVID-19. Diabetes/Metabolism Research and Reviews, 2022, 38, e3526. | 1.7 | 10 |
| 664 | Role of antibodies, inflammatory markers, and echocardiographic findings in postacute cardiopulmonary symptoms after SARS-CoV-2 infection. JCI Insight, 2022, 7, . | 2.3 | 24 |
| 665 | Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities. JAMA Internal Medicine, 2022, 182, 426. | 2.6 | 69 |
| 666 | COVID-19 Induced Cardiomyopathy Successfully Treated with Tocilizumab. Case Reports in Cardiology, 2022, 2022, 1-6. | 0.1 | 5 |
| 667 | COVID-19 therapeutics: Challenges and directions for the future. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119893119. | 3.3 | 92 |
| 668 | Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. Frontiers in Immunology, 2022, 13, 871592. | 2.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 669 | The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections. <i>Frontiers in Immunology</i> , 2022, 13, 832394. | 2.2 | 56 |
| 670 | Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials. <i>European Journal of Internal Medicine</i> , 2022, 101, 41-48. | 1.0 | 12 |
| 672 | Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial. <i>Critical Care</i> , 2022, 26, 101. | 2.5 | 19 |
| 673 | WHO Ordinal Scale and Inflammation Risk Categories in COVID-19. Comparative Study of the Severity Scales. <i>Journal of General Internal Medicine</i> , 2022, 37, 1980-1987. | 1.3 | 27 |
| 674 | Effect of Antiplatelet Therapy on Survival and Organ Support—Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247. | 3.8 | 83 |
| 675 | Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study. <i>Medicina (Lithuania)</i> , 2022, 58, 513. | 0.8 | 16 |
| 676 | A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19. <i>Med</i> , 2022, 3, 233-248.e6. | 2.2 | 17 |
| 677 | Percutaneous coronary intervention during the COVID-19 pandemic in Japan: Insights from the nationwide registration data. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 22, 100434. | 1.3 | 16 |
| 678 | Platelet-leukocyte crosstalk in COVID-19: How might the reciprocal links between thrombotic events and inflammatory state affect treatment strategies and disease prognosis?. <i>Thrombosis Research</i> , 2022, 213, 179-194. | 0.8 | 17 |
| 679 | Clinical update on COVID-19 for the emergency and critical care clinician: Medical management. <i>American Journal of Emergency Medicine</i> , 2022, 56, 158-170. | 0.7 | 13 |
| 680 | Endothelial dysfunction in acute and long standing COVID-19: A prospective cohort study. <i>Vascular Pharmacology</i> , 2022, 144, 106975. | 1.0 | 66 |
| 681 | Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study. <i>International Immunopharmacology</i> , 2022, 107, 108709. | 1.7 | 3 |
| 682 | Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19. <i>International Immunopharmacology</i> , 2022, 107, 108689. | 1.7 | 2 |
| 683 | Outcome of Critically Ill COVID-19 Patients According to the Setting of Corticosteroid Initiation—A Retrospective Observational Cohort Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1359. | 1.1 | 1 |
| 684 | COVID-19 in patients with glomerular disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 191-198. | 1.0 | 1 |
| 685 | ¿Cuál es la utilidad del bloqueo de interleuquina-6 en pacientes con COVID-19?. <i>Revista Del Hospital Italiano De Buenos Aires</i> , 2021, 41, 193-195. | 0.0 | 0 |
| 686 | Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687. | 1.8 | 3 |
| 687 | Higher versus lower oxygenation targets in COVID-19 patients with severe hypoxaemia (HOT-COVID) trial: Protocol for a secondary Bayesian analysis. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 408-414. | 0.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 688 | Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638. | 1.0 | 39 |
| 690 | Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. <i>Clinical Pharmacokinetics</i> , 2022, 61, 155-165. | 1.6 | 8 |
| 691 | Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5815. | 1.0 | 6 |
| 692 | <sc>COVID-19</sc> and critical care capacity: Can we mitigate demand?. <i>Respirology</i> , 2022, 27, 107-108. | 1.3 | 3 |
| 693 | Al ₂ O ₃ referenced microring resonators for the detection of interleukin-6. , 2021, , . | | 0 |
| 694 | Adult Still's disease: New horizons. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 645-665. | 0.2 | 6 |
| 695 | Clinical trials during the COVID-19 pandemic: research design and lessons. , 2021, , 214-231. | | 0 |
| 696 | Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab581. | 0.4 | 16 |
| 697 | Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 763292. | 2.2 | 50 |
| 699 | Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study. <i>Respiratory Research</i> , 2021, 22, 317. | 1.4 | 11 |
| 700 | COVID-19: management in the ICU. , 2021, , 124-143. | | 2 |
| 701 | Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e516-e524. | 2.9 | 44 |
| 702 | The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations. <i>Lancet Infectious Diseases</i> , The, 2022, 22, e153-e158. | 4.6 | 22 |
| 705 | Covid-19 in recipients of living donor liver transplantation: a worse or an equivalent outcome?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 69-76. | 0.2 | 3 |
| 707 | COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 737257. | 1.1 | 33 |
| 708 | COVID-19: The question of genetic diversity and therapeutic intervention approaches. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200452. | 0.6 | 1 |
| 709 | Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes. <i>Rheumatology and Immunology Research</i> , 2022, 3, 11-16. | 0.2 | 2 |
| 710 | Effectiveness of Tocilizumab in Patients with Severe or Critical Lung Involvement in COVID-19: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 2286. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 711 | Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19. <i>Clinical Pharmacokinetics</i> , 2022, 61, 973-983. | 1.6 | 5 |
| 712 | Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. <i>Journal of Virology</i> , 2022, 96, e0005722. | 1.5 | 14 |
| 713 | Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients. <i>Journal of Fungi (Basel)</i> , 2022, 9, 11. | 1.5 | 11 |
| 714 | Cyclosporin A Reveals Potent Antiviral Effects in Preclinical Models of SARS-CoV-2 Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 964-968. | 2.5 | 5 |
| 715 | Critically Ill Pediatric Patient and SARS-CoV-2 Infection. <i>Children</i> , 2022, 9, 538. | 0.6 | 3 |
| 716 | COVID-19 Infection in Children: Diagnosis and Management. <i>Current Infectious Disease Reports</i> , 2022, 24, 51-62. | 1.3 | 25 |
| 717 | Caring for the Critically Ill Patient with COVID-19. <i>Clinics in Chest Medicine</i> , 2022, 43, 441-456. | 0.8 | 1 |
| 719 | Senicapoc treatment in COVID-19 Patients with Severe Respiratory Insufficiency: A Randomized, Open-Label, Phase II Trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, , . | 0.7 | 3 |
| 720 | COVID-19 Autopsies Reveal Underreporting of SARS-CoV-2 Infection and Scarcity of Co-infections. <i>Frontiers in Medicine</i> , 2022, 9, 868954. | 1.2 | 14 |
| 721 | Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. <i>Process Biochemistry</i> , 2022, 118, 154-170. | 1.8 | 4 |
| 722 | Sarilumab administration in patients with severe COVID-19: A report of four cases and a literature review. <i>World Academy of Sciences Journal</i> , 2022, 4, . | 0.4 | 3 |
| 723 | Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure. <i>Clinical Immunology</i> , 2022, 238, 109016. | 1.4 | 15 |
| 724 | JAK inhibitors and COVID-19. , 2022, 10, e002838. | | 34 |
| 725 | An Adaptive Information Borrowing Platform Design for Testing Drug Candidates of COVID-19. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13. | 0.7 | 0 |
| 727 | Prevalence, prognostic value, pathophysiology, and management of hyponatraemia in children and adolescents with COVID-19. <i>Acta Biomedica</i> , 2021, 92, e2021474. | 0.2 | 2 |
| 728 | Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.. <i>Acta Biomedica</i> , 2022, 93, e2022014. | 0.2 | 5 |
| 730 | Coronavirus disease 2019 pandemic two years later: What's next?. <i>Croatian Medical Journal</i> , 2022, 63, 1-5. | 0.2 | 0 |
| 731 | Association of discharge policy with the length of hospital stay among patients with coronavirus disease 2019: a cross-sectional study.. <i>Croatian Medical Journal</i> , 2022, 63, 71-78. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 733 | Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19. <i>Yonsei Medical Journal</i> , 2022, 63, 430. | 0.9 | 6 |
| 734 | Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. <i>Scientific Reports</i> , 2022, 12, 6843. | 1.6 | 12 |
| 735 | Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 301-307. | 0.1 | 2 |
| 736 | The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. <i>Covid</i> , 2022, 2, 540-552. | 0.7 | 12 |
| 737 | Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study. <i>Japanese Journal of Infectious Diseases</i> , 2022, 75, 484-489. | 0.5 | 4 |
| 738 | Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. <i>Value in Health</i> , 2022, , . | 0.1 | 5 |
| 739 | SARS-CoV-2 and Multiple Sclerosis: Potential for Disease Exacerbation. <i>Frontiers in Immunology</i> , 2022, 13, 871276. | 2.2 | 13 |
| 740 | T2-low: what do we know?. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 150-159. | 0.5 | 11 |
| 741 | Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update. <i>Clinical Immunology</i> , 2022, 239, 109022. | 1.4 | 12 |
| 742 | Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. <i>Audiology Research</i> , 2022, 12, 224-248. | 0.8 | 6 |
| 743 | Motivating factors, barriers and facilitators of participation in COVID-19 clinical research: A cross-sectional survey of Canadian community intensive care units. <i>PLoS ONE</i> , 2022, 17, e0266770. | 1.1 | 1 |
| 744 | Committee report: Questionnaire survey on the treatment of COVID-19 in patients receiving dialysis therapy. <i>Renal Replacement Therapy</i> , 2022, 8, 18. | 0.3 | 3 |
| 745 | Myeloid-Derived Suppressor Cells in COVID-19: The Paradox of Good. <i>Frontiers in Immunology</i> , 2022, 13, 842949. | 2.2 | 16 |
| 746 | Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections. <i>Journal of Hospital Infection</i> , 2022, 126, 29-36. | 1.4 | 7 |
| 747 | Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). <i>Leukemia</i> , 2022, 36, 1467-1480. | 3.3 | 63 |
| 748 | Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective. <i>Current Vascular Pharmacology</i> , 2022, 20, 333-340. | 0.8 | 1 |
| 749 | Calprotectin and Imbalances between Acute-Phase Mediators Are Associated with Critical Illness in COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4894. | 1.8 | 17 |
| 750 | Rapid Quantum Magnetic IL-6 Point-of-Care Assay in Patients Hospitalized with COVID-19. <i>Diagnostics</i> , 2022, 12, 1164. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 751 | Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study. , 2022, 4, e0696. | | 9 |
| 752 | Treatment strategies of Covid-19. A rheumatology perspective.. European Journal of Internal Medicine, 2022, , . | 1.0 | 3 |
| 753 | COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic. BMC Nephrology, 2022, 23, 183. | 0.8 | 16 |
| 755 | Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. Infectious Disease Reports, 2022, 14, 360-371. | 1.5 | 14 |
| 756 | Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study. , 2022, 4, e0702. | | 10 |
| 757 | Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. Nature Communications, 2022, 13, 2583. | 5.8 | 25 |
| 758 | The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses. Frontiers in Immunology, 2022, 13, . | 2.2 | 4 |
| 759 | Tocilizumab in patients hospitalised with COVID-19 pneumonia: Efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine, 2022, 47, 101409. | 3.2 | 20 |
| 760 | Type I interferon regulates proteolysis by macrophages to prevent immunopathology following viral infection. PLoS Pathogens, 2022, 18, e1010471. | 2.1 | 5 |
| 761 | Relationship between SARS-CoV-2 antibody titer and the severity of COVID-19. Journal of Microbiology, Immunology and Infection, 2022, 55, 1094-1100. | 1.5 | 9 |
| 762 | Significance of hyperferritinemia as a diagnostic and prognostic biomarker. Sovremennaya Revmatologiya, 2022, 16, 74-80. | 0.1 | 2 |
| 763 | How to Study the Brain While Anesthetizing It?! A Scoping Review on Running Neuroanesthesiologic Studies and Trials That Include Neurosurgical Patients. World Neurosurgery, 2022, 161, 376-381. | 0.7 | 1 |
| 765 | The Impact of Cytokines on Neutrophils' Phagocytosis and NET Formation during Sepsis A Review. International Journal of Molecular Sciences, 2022, 23, 5076. | 1.8 | 7 |
| 766 | Understanding the People Excluded from Chronic Obstructive Pulmonary Disease Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 235-236. | 2.5 | 1 |
| 767 | The utility of CRP with the use of dexamethasone and Tocilizumab in critically ill patients with COVID-19. Journal of Critical Care, 2022, 70, 154053. | 1.0 | 3 |
| 768 | Tocilizumab Accelerates Recovery in Patients With Severe COVID-19 Pneumonia on Venovenous Extracorporeal Membrane Oxygenation. ASAIO Journal, 2022, 68, 1010-1016. | 0.9 | 3 |
| 769 | Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. Trials, 2022, 23, 401. | 0.7 | 3 |
| 771 | Artificial Intelligence-Based Pharmacovigilance in the Setting of Limited Resources. Drug Safety, 2022, 45, 511-519. | 1.4 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 772 | Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis. <i>Critical Care</i> , 2022, 26, 141. | 2.5 | 9 |
| 773 | A Randomized Double-Blinded Placebo Controlled Trial of Clazakizumab for the Treatment of COVID-19 Pneumonia With Hyperinflammation*. <i>Critical Care Medicine</i> , 2022, 50, 1348-1359. | 0.4 | 8 |
| 774 | TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 178-187. | 1.5 | 15 |
| 775 | COVID-19 Myocarditis: An Emerging Clinical Conundrum. <i>Current Problems in Cardiology</i> , 2022, 47, 101268. | 1.1 | 12 |
| 776 | Severe acute respiratory syndrome coronavirus 2 infection: Role of interleukin-6 and the inflammatory cascade. <i>World Journal of Virology</i> , 2022, 11, 113-128. | 1.3 | 5 |
| 777 | Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review. , 2022, 10, 251513552210975. | 1.4 | 6 |
| 778 | Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 8 |
| 779 | Prognostic Factors Associated With Mortality of Patients With COVID-19 Requiring Ventilator Management: A Retrospective Cohort Study. <i>Cureus</i> , 2022, , . | 0.2 | 1 |
| 780 | The Safety and Efficacy of Tocilizumab in Older Adult Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Multi-center, Cohort Study. <i>International Journal of Infectious Diseases</i> , 2022, , . | 1.5 | 5 |
| 781 | COVID 19 pandemic challenges and their management: A review of medicines, vaccines, patents and clinical trials with emphasis on psychological health issues. <i>Saudi Pharmaceutical Journal</i> , 2022, , . | 1.2 | 1 |
| 782 | Current Strategies in Treating Cytokine Release Syndrome Triggered by Coronavirus SARS-CoV-2. <i>ImmunoTargets and Therapy</i> , 0, Volume 11, 23-35. | 2.7 | 3 |
| 783 | Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2022, 9, 185-198. | 0.9 | 3 |
| 784 | Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L14-L26. | 1.3 | 15 |
| 785 | An Approach to the Treatment of Children With COVID-19. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 654-662. | 1.1 | 5 |
| 786 | Key Considerations for Phase 2 or 3 Clinical Study Design of Anti-Inflammatory Agent for COVID-19 Treatment. <i>Frontiers in Pharmacology</i> , 2022, 13, . | 1.6 | 0 |
| 787 | A systems biology approach identifies candidate drugs to reduce mortality in severely ill patients with COVID-19. <i>Science Advances</i> , 2022, 8, . | 4.7 | 14 |
| 789 | Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0269368. | 1.1 | 11 |
| 790 | Prognostic implications of comorbidity patterns in critically ill COVID-19 patients: A multicenter, observational study. <i>Lancet Regional Health - Europe</i> , The, 2022, 18, 100422. | 3.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 791 | Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial. <i>In Vivo</i> , 2022, 36, 1959-1965. | 0.6 | 3 |
| 792 | Management of Acute Respiratory Distress Syndrome in COVID-19 Patients. <i>Acta Anaesthesiologica Belgica</i> , 2022, 73, 5-14. | 0.0 | 0 |
| 793 | Calcific aortic valve stenosis and COVID-19: clinical management, valvular damage, and pathophysiological mechanisms. <i>Cardiology Plus</i> , 2022, 7, 3-11. | 0.2 | 0 |
| 794 | Severe Neutropenia after Sarilumab Administration in Two COVID-19 Patients: Case Reports and Literature Review. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 142-147. | 0.1 | 1 |
| 795 | A REVIEW: TOCILIZUMAB, A RAY OF HOPE IN COVID-19 PNEUMONIA. <i>Innovare Journal of Medical Sciences</i> , 0, , 14-16. | 0.2 | 0 |
| 796 | The Role of IL-6 in RNA Virus Infection. , 0, , . | | 0 |
| 797 | Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 509-518. | 0.1 | 0 |
| 798 | The IL-1 β , IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. <i>Cell Reports Medicine</i> , 2022, 3, 100663. | 3.3 | 175 |
| 799 | The <i>Staphylococcus aureus</i> Network Adaptive Platform Trial Protocol: New Tools for an Old Foe. <i>Clinical Infectious Diseases</i> , 2022, 75, 2027-2034. | 2.9 | 27 |
| 800 | Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, . | 7.1 | 31 |
| 801 | Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19. <i>Lancet Respiratory Medicine</i> , 2022, 10, 700-714. | 5.2 | 22 |
| 802 | Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919. | 2.1 | 23 |
| 803 | New Insights into Clinical and Mechanistic Heterogeneity of the Acute Respiratory Distress Syndrome: Summary of the Aspen Lung Conference 2021. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 284-308. | 1.4 | 9 |
| 804 | Redefining critical illness. <i>Nature Medicine</i> , 2022, 28, 1141-1148. | 15.2 | 136 |
| 805 | The AI-Assisted Identification and Clinical Efficacy of Baricitinib in the Treatment of COVID-19. <i>Vaccines</i> , 2022, 10, 951. | 2.1 | 8 |
| 806 | The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 3 |
| 807 | Death and invasive mechanical ventilation risk in hospitalized COVID-19 patients treated with anti-SARS-CoV-2 monoclonal antibodies and/or antiviral agents: A systematic review and network meta-analysis protocol. <i>PLoS ONE</i> , 2022, 17, e0270196. | 1.1 | 3 |
| 808 | An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Ethical and <sc>US</sc> regulatory considerations. <i>Transfusion</i> , 2022, 62, . | 0.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 809 | An adaptive platform trial for evaluating treatments in patients with life-threatening hemorrhage from traumatic injuries: Planning and execution. <i>Transfusion</i> , 2022, 62, . | 0.8 | 2 |
| 810 | People in intensive care with <scp>COVID</scp> â€19: demographic and clinical features during the first, second, and third pandemic waves in Australia. <i>Medical Journal of Australia</i> , 2022, 217, 352-360. | 0.8 | 23 |
| 811 | Biologics in COVID-19 So Far: Systematic Review. <i>Pharmaceuticals</i> , 2022, 15, 783. | 1.7 | 5 |
| 813 | Evaluation of perturbed iron-homeostasis in a prospective cohort of patients with COVID-19. <i>Wellcome Open Research</i> , 0, 7, 173. | 0.9 | 4 |
| 814 | Application of Monoclonal Antibody Drugs in Treatment of COVID-19: a Review. <i>BioNanoScience</i> , 2022, 12, 1436-1454. | 1.5 | 2 |
| 815 | Longer Steroid Treatment Increases Secondary Bloodstream Infection Risk Among Patients With COVID-19 Requiring Intensive Care. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, . | 0.1 | 3 |
| 816 | A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection. <i>Infectious Disease Reports</i> , 2022, 14, 446-452. | 1.5 | 8 |
| 817 | Investigation of target sequencing of SARS-CoV-2 and immunogenic GWAS profiling in host cells of COVID-19 in Vietnam. <i>BMC Infectious Diseases</i> , 2022, 22, . | 1.3 | 2 |
| 818 | Predictors of Mortality in Tocilizumab-Treated Severe COVID-19. <i>Vaccines</i> , 2022, 10, 978. | 2.1 | 2 |
| 819 | Host-directed immunotherapy of viral and bacterial infections: past, present and future. <i>Nature Reviews Immunology</i> , 2023, 23, 121-133. | 10.6 | 71 |
| 820 | Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. <i>IScience</i> , 2022, 25, 104612. | 1.9 | 9 |
| 821 | Profiling Differential Effects of 5 Selective Serotonin Reuptake Inhibitors on TLRs-Dependent and -Independent IL-6 Production in Immune Cells Identifies Fluoxetine as Preferred Anti-Inflammatory Drug Candidate. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 4 |
| 822 | Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 7 |
| 823 | Tocilizumab Treatment Reduces Mortality in Hospitalized Patients With COVID-19: A Retrospective Cohort Study at a New York City Hospital. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, . | 0.1 | 1 |
| 824 | Urine metabolomics links dysregulation of the tryptophan-kynurenine pathway to inflammation and severity of COVID-19. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 18 |
| 825 | Maternal plasma cytokines and the subsequent risk of uterine atony and postpartum hemorrhage. <i>Journal of Perinatal Medicine</i> , 2023, 51, 219-232. | 0.6 | 2 |
| 826 | Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 608-612. | 0.1 | 0 |
| 827 | Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2022, 60, 2200803. | 3.1 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 828 | High generation of reactive oxygen species from neutrophils in patients with severe COVID-19. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 26 |
| 829 | Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. <i>Lancet Rheumatology</i> , The, 2022, 4, e490-e506. | 2.2 | 61 |
| 830 | Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent. <i>Cytokine</i> , 2022, 157, 155934. | 1.4 | 19 |
| 831 | Diretrizes Brasileiras para o tratamento farmacológico de pacientes hospitalizados com COVID-19. <i>Revista Brasileira De Terapia Intensiva</i> , 2022, 34, . | 0.1 | 2 |
| 832 | è...¹è†œé€œžã*æ-°ãž<ã,³ãfãfŠã, ã,ãf«ã,¹æ,,ÿæÿ“ç-‡. <i>Nihon Toseki Igakkai Zasshi</i> , 2022, 55, 371-377. | 0.2 | 0 |
| 833 | Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. <i>Transplantation</i> , 2022, 106, 1528-1537. | 0.5 | 23 |
| 834 | Does Tocilizumab Influence the Outcome of Patients with COVID-19 Pneumonia Compared to the Standard Therapy? Retrospective Analysis of Data Obtained during Phase I COVID Pandemic. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 1383-1391. | 0.1 | 0 |
| 835 | Induction of a cytokine storm involves suppression of the <scp>Osteopontin&Edependent TH1</scp> response. <i>Immunology</i> , 2022, 167, 165-180. | 2.0 | 2 |
| 836 | Pharmacological Studies in Hospitalized COVID-19 Patients in Belgium: We Could Do Better. <i>Viruses</i> , 2022, 14, 1427. | 1.5 | 1 |
| 837 | How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies. <i>Blood</i> , 2022, 140, 673-684. | 0.6 | 20 |
| 838 | An autopsy case of <scp>COVID</scp> â€19 with a sudden death: Clinico&Epathological comparison. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, . | 0.2 | 3 |
| 839 | Emerging clinical trial designs may accelerate translation in hematology: lessons from COVID-19. <i>Blood Advances</i> , 2022, 6, 4710-4714. | 2.5 | 5 |
| 840 | Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L372-L389. | 1.3 | 9 |
| 841 | COVID-19 Mortality and Therapeutics in Nebraska and Southwest Iowa during Early Pandemic. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 69. | 0.6 | 0 |
| 842 | Attenuation of <scp>SARS&ECoV</scp> â€2 replication and associated inflammation by concomitant targeting of viral and host cap 2'â€O&Eribose methyltransferases. <i>EMBO Journal</i> , 2022, 41, . | 3.5 | 18 |
| 844 | Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7702. | 1.8 | 2 |
| 845 | The Application of Bayesian Methods to Help Interpret the VANCO Trial Results. <i>Journal of Orthopaedic Trauma</i> , 2022, Publish Ahead of Print, . | 0.7 | 2 |
| 846 | Dynamics of disease characteristics and clinical management of critically ill COVID-19 patients over the time course of the pandemic: an analysis of the prospective, international, multicentre RISC-19-ICU registry. <i>Critical Care</i> , 2022, 26, . | 2.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 847 | C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 "LIVE-AIR"™ trial. <i>Thorax</i> , 0, , thoraxjnl-2022-218744. | 2.7 | 3 |
| 848 | Early Experience With Interleukin-6 Receptor Antagonists in Patients With COVID-19 Admitted to a Community Hospital. <i>Journal of Pharmacy Technology</i> , 0, , 875512252211043. | 0.5 | 0 |
| 850 | Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19. <i>Meditinskiy Sovet</i> , 2022, , 88-94. | 0.1 | 0 |
| 851 | Optimizing the Design and Analysis of Future AKI Trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1459-1470. | 3.0 | 17 |
| 852 | Performance evaluation of a multinational data platform for critical care in Asia. <i>Wellcome Open Research</i> , 0, 6, 251. | 0.9 | 8 |
| 853 | Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. <i>Clinical Trials</i> , 2022, 19, 561-572. | 0.7 | 2 |
| 854 | Tocilizumab therapy for IL-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome. <i>International Journal of Infectious Diseases</i> , 2022, 122, 656-658. | 1.5 | 2 |
| 855 | Dengue and COVID-19: two sides of the same coin. <i>Journal of Biomedical Science</i> , 2022, 29, . | 2.6 | 16 |
| 856 | Management of Severe and Critical COVID-19 Infection with Immunotherapies. <i>Infectious Disease Clinics of North America</i> , 2022, , . | 1.9 | 0 |
| 857 | Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0270668. | 1.1 | 16 |
| 858 | Pharmacy students' knowledge and confidence of COVID-19 following an interactive didactic class. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2022, 5, 1082-1087. | 0.5 | 3 |
| 859 | Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 269-297. | 0.8 | 2 |
| 860 | Clinical and survival differences during separate COVID-19 surges: Investigating the impact of the Sars-CoV-2 alpha variant in critical care patients. <i>PLoS ONE</i> , 2022, 17, e0269244. | 1.1 | 3 |
| 861 | MSC-Exosomes Carrying miRNA " Could they Enhance Tocilizumab Activity in Neuropathology of COVID-19?. <i>Stem Cell Reviews and Reports</i> , 2023, 19, 279-283. | 1.7 | 3 |
| 862 | The Pitfalls of Mining for QuantiFERON Gold in Severely Ill Patients With COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2022, 6, 409-419. | 1.2 | 2 |
| 863 | Effect of treatment regimens in severe COVID pneumonia at an Indian tertiary care hospital: An observational, real-world study. <i>Medical Journal Armed Forces India</i> , 2022, 78, 469-474. | 0.3 | 0 |
| 864 | The SARS-CoV-2 Nucleoprotein Induces Innate Memory in Human Monocytes. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 3 |
| 865 | Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study. <i>Critical Care</i> , 2022, 26, . | 2.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 866 | JAK inhibition as a new treatment strategy for patients with COVID-19. <i>Biochemical Pharmacology</i> , 2022, 202, 115162. | 2.0 | 10 |
| 867 | “Ventilator-free days” composite outcome in patients with SARS-CoV-2 infection treated with tocilizumab: A retrospective competing risk analysis. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2022, 56, 118-124. | 0.8 | 1 |
| 868 | Aspectos clínicos de la COVID-19. <i>Ambiociencias</i> , 0, , 7-22. | 0.0 | 0 |
| 869 | How to conduct collaborative research studies. <i>Anaesthesia</i> , 2023, 78, 251-255. | 1.8 | 0 |
| 870 | Critical patients COVID-19 has changed the management and outcomes in the ICU after 1 year of the pandemic? A multicenter, prospective, observational study. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2022, , . | 0.2 | 0 |
| 871 | Antiviral treatment for COVID-19: ensuring evidence is applicable to current circumstances. <i>Cmaj</i> , 2022, 194, E996-E997. | 0.9 | 1 |
| 872 | Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. <i>Science Translational Medicine</i> , 2022, 14, . | 5.8 | 27 |
| 873 | The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 5 |
| 875 | Systemic sclerosis in the time of COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e566-e575. | 2.2 | 14 |
| 876 | Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 187-209. | 1.0 | 5 |
| 877 | COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress. <i>Cancers</i> , 2022, 14, 3711. | 1.7 | 6 |
| 878 | Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. <i>European Respiratory Journal</i> , 2022, 60, 2200780. | 3.1 | 15 |
| 879 | Beneficial and Harmful Effects of Monoclonal Antibodies for the Treatment and Prophylaxis of COVID-19: Systematic Review and Meta-Analysis. <i>American Journal of Medicine</i> , 2022, 135, 1349-1361.e18. | 0.6 | 11 |
| 880 | Applying Lessons Learned From COVID-19 Therapeutic Trials to Improve Future ALI/ARDS Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, . | 0.4 | 6 |
| 881 | Proteomic analysis of cardiometabolic biomarkers and predictive modeling of severe outcomes in patients hospitalized with COVID-19. <i>Cardiovascular Diabetology</i> , 2022, 21, . | 2.7 | 0 |
| 882 | Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7937. | 1.8 | 2 |
| 883 | Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2023, 29, 13-21. | 2.8 | 19 |
| 884 | The role of interleukin-22 in lung health and its therapeutic potential for COVID-19. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 885 | Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework. <i>Journal of Clinical Medicine</i> , 2022, 11, 4464. | 1.0 | 13 |
| 886 | Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases. <i>Journal of Translational Medicine</i> , 2022, 20, . | 1.8 | 1 |
| 887 | Characteristics and risk factors for mortality in critically ill patients with COVID-19 receiving invasive mechanical ventilation: the experience of a private network in Sao Paulo, Brazil. <i>The Journal of Critical Care Medicine</i> , 2022, 8, 165-175. | 0.3 | 0 |
| 888 | Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial. <i>Open Forum Infectious Diseases</i> , 2022, 9, . | 0.4 | 15 |
| 889 | COVID-19 Secondary Infections in ICU Patients and Prevention Control Measures: A Preliminary Prospective Multicenter Study. <i>Antibiotics</i> , 2022, 11, 1016. | 1.5 | 1 |
| 890 | Coagulopathy in COVID-19 and anticoagulation clinical trials. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101377. | 0.7 | 3 |
| 891 | Eosinophil Levels, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio in the Cytokine Storm Period of Patients with COVID-19. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-6. | 0.8 | 5 |
| 892 | Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0271807. | 1.1 | 10 |
| 893 | Role of aging in Bloodâ€“Brain Barrier dysfunction and susceptibility to SARS-CoV-2 infection: impacts on neurological symptoms of COVID-19. <i>Fluids and Barriers of the CNS</i> , 2022, 19, . | 2.4 | 10 |
| 894 | Natriuretic peptide receptor-C mediates the inhibitory effect of atrial natriuretic peptide on neutrophil recruitment to the lung during acute lung injury. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L438-L449. | 1.3 | 2 |
| 895 | Combination therapy with remdesivir and immunomodulators improves respiratory status in COVIDâ€“19: A retrospective study. <i>Journal of Medical Virology</i> , 2022, 94, 5702-5712. | 2.5 | 7 |
| 896 | Should RECOVERY have used response adaptive randomisation? Evidence from a simulation study. <i>BMC Medical Research Methodology</i> , 2022, 22, . | 1.4 | 2 |
| 897 | Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?. <i>Viruses</i> , 2022, 14, 1860. | 1.5 | 0 |
| 898 | Mid-regional Proadrenomedullin Biomarker Predicts Coronavirus Disease 2019 Clinical Outcomes: A US-Based Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, . | 0.4 | 2 |
| 899 | Moving to the Head of the â€œClazaâ€“ Targeting Interleukin-6 for COVID-19 Pneumonia. <i>Critical Care Medicine</i> , 2022, 50, 1406-1408. | 0.4 | 0 |
| 901 | Characterization of pathogenâ€“inactivated <sc>COVID</sc>â€“19 convalescent plasma and responses in transfused patients. <i>Transfusion</i> , 2022, 62, 1997-2011. | 0.8 | 7 |
| 902 | Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19. <i>Cureus</i> , 2022, , . | 0.2 | 1 |
| 903 | Care of the Seriously Ill Patient with SARS CoV-2. <i>Medical Clinics of North America</i> , 2022, , . | 1.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 905 | Immunomodulatory therapies for COVID-19. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 3 |
| 906 | Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 773-787. | 0.5 | 11 |
| 907 | An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. <i>Cancers</i> , 2022, 14, 3931. | 1.7 | 2 |
| 909 | Cryptococcal Pneumonia: An Unusual Complication in a COVID-19 Patient. <i>Diagnostics</i> , 2022, 12, 1944. | 1.3 | 4 |
| 910 | Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series. <i>Journal of the Nepal Medical Association</i> , 2022, 60, 727-731. | 0.1 | 1 |
| 911 | COVID-19-associated fungal infections. <i>Nature Microbiology</i> , 2022, 7, 1127-1140. | 5.9 | 183 |
| 912 | Analysis of Chitinase-3-Like Protein 1, IL-1-Alpha, and IL-6 as Novel Inflammatory Biomarkers for COVID-19. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 536-541. | 0.5 | 3 |
| 913 | Analysis of adaptive platform trials using a network approach. <i>Clinical Trials</i> , 2022, 19, 479-489. | 0.7 | 5 |
| 915 | SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy. <i>Pediatric Research</i> , 2023, 93, 1375-1382. | 1.1 | 4 |
| 916 | Interstitial Lung Fibrosis Following COVID-19 Pneumonia. <i>Diagnostics</i> , 2022, 12, 2028. | 1.3 | 10 |
| 917 | Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). <i>Journal of Intensive Medicine</i> , 2022, 2, 199-222. | 0.8 | 3 |
| 918 | Immune-related adverse events of biological immunotherapies used in COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 2 |
| 919 | Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101375. | 0.7 | 0 |
| 920 | The Characteristics of Patients with Severe COVID-19 Pneumonia Treated with Direct Hemoperfusion Using Polymyxin B-Immobilized Fiber Column (PMX-DHP). <i>Infection and Drug Resistance</i> , 0, Volume 15, 4819-4828. | 1.1 | 0 |
| 921 | Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2022, 53, 3410-3418. | 1.0 | 4 |
| 922 | Application of Machine Learning in Hospitalized Patients with Severe COVID-19 Treated with Tocilizumab. <i>Journal of Clinical Medicine</i> , 2022, 11, 4729. | 1.0 | 3 |
| 923 | Incidence and risk factors of COVID-19 associated pneumothorax. <i>PLoS ONE</i> , 2022, 17, e0271964. | 1.1 | 13 |
| 924 | Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study. <i>Antibiotics</i> , 2022, 11, 1078. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 925 | Severe coronavirus disease 2019 in a patient with TAFRO syndrome: A case report. <i>Clinical Infection in Practice</i> , 2022, 16, 100158. | 0.2 | 2 |
| 926 | Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. <i>Lancet</i> , The, 2022, 400, 1145-1156. | 6.3 | 129 |
| 927 | Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID-19 patients: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2022, 32, . | 3.9 | 13 |
| 928 | Systemic interleukin-6 inhibition ameliorates acute neuropsychiatric phenotypes in a murine model of acute lung injury. <i>Critical Care</i> , 2022, 26, . | 2.5 | 5 |
| 929 | Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a prospective multicentre cohort study. <i>The Lancet Digital Health</i> , 2022, 4, e727-e737. | 5.9 | 15 |
| 930 | IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden. <i>Cytokine</i> , 2022, 159, 156020. | 1.4 | 2 |
| 931 | COVID-19 in patients with B cell immune deficiency. <i>Journal of Immunological Methods</i> , 2022, 510, 113351. | 0.6 | 1 |
| 932 | Long-term cognitive performance and its relation to anti-inflammatory therapy in a cohort of survivors of severe COVID-19. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 25, 100513. | 1.3 | 10 |
| 933 | A meta-summary and bioinformatic analysis identified interleukin 6 as a master regulator of COVID-19 severity biomarkers. <i>Cytokine</i> , 2022, 159, 156011. | 1.4 | 10 |
| 934 | Efficacy of intravenous vitamin C in management of moderate and severe COVID-19: A double blind randomized placebo controlled trial. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4758. | 0.3 | 2 |
| 935 | Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors. <i>Mediterranean Journal of Rheumatology</i> , 2022, 33, 173. | 0.3 | 1 |
| 936 | Circadian Rhythm, Sleep, and Immune Response and the Fight against COVID-19. <i>Oman Medical Journal</i> , 2023, 38, e477-e477. | 0.3 | 2 |
| 937 | Pre-hospital Management of COVID-19: Looking for a Future Perspective. , 2022, , 395-419. | | 0 |
| 938 | Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211164. | 1.2 | 2 |
| 939 | Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. <i>CMAJ Open</i> , 2022, 10, E807-E817. | 1.1 | 2 |
| 940 | Strategies for Cardio-Oncology Care During the COVID-19 Pandemic. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2022, 24, 137-153. | 0.4 | 2 |
| 941 | Perspective: repurposed Drugs for COVID-19. <i>Archives of Medical Science</i> , 2022, 18, 1378-1391. | 0.4 | 3 |
| 942 | Efficacy of umbilical cord mesenchymal stromal cells for COVID-19: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 944 | Clinical characteristics analysis of COVID-19 patients from the first significant community outbreak by SARS-CoV-2 variant B.1.1.7 in Taiwan as experienced from a single northern medical center. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 1036-1043. | 1.5 | 7 |
| 945 | Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. <i>Intensive Care Medicine</i> , 2022, 48, 1525-1538. | 3.9 | 13 |
| 946 | The Role of Master Protocols in Pediatric Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 895-902. | 0.8 | 7 |
| 947 | COVID-19 Related Myocarditis in Adults: A Systematic Review of Case Reports. <i>Journal of Clinical Medicine</i> , 2022, 11, 5519. | 1.0 | 12 |
| 948 | Galectin-3 Inhibition in COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 207, 118-120. | 2.5 | 5 |
| 949 | Assessment of the effectiveness of tocilizumab on mortality and progression to mechanical ventilation or intensive care in patients with COVID-19 admitted to a tertiary hospital. <i>European Journal of Hospital Pharmacy</i> , 0, , ejhpharm-2022-003366. | 0.5 | 1 |
| 950 | Safety and effectiveness of RBD-specific polyclonal equine F(ab ²) fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0274796. | 1.1 | 0 |
| 951 | Audio-Vestibular Side Effects of Drugs and Vaccines in Treatment of COVID-19. , 0, , . | | 0 |
| 952 | Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, . | 1.2 | 8 |
| 953 | The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro. <i>Biomedicines</i> , 2022, 10, 2324. | 1.4 | 6 |
| 954 | Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022). <i>Transplantation and Cellular Therapy</i> , 2022, 28, 810-821. | 0.6 | 9 |
| 955 | Traumatic brain injury: progress and challenges in prevention, clinical care, and research. <i>Lancet Neurology</i> , The, 2022, 21, 1004-1060. | 4.9 | 197 |
| 956 | Obesity and coronavirus disease 2019. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 207-218. | 1.0 | 3 |
| 957 | Impact of monocyte-related modulators and kidney function on mortality in hospitalized patients with COVID-19. <i>Scandinavian Journal of Immunology</i> , 2022, 96, . | 1.3 | 1 |
| 958 | A practical update on the management of patients with COVID-19. <i>Clinical Medicine</i> , 2022, 22, 468-474. | 0.8 | 2 |
| 959 | Saving millions of lives but some resources squandered: emerging lessons from health research system pandemic achievements and challenges. <i>Health Research Policy and Systems</i> , 2022, 20, . | 1.1 | 5 |
| 960 | COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. , 2022, 10, e0051111. | | 17 |
| 962 | Electrochemiluminescence in paired signal electrode (ECLipse) enables modular and scalable biosensing. <i>Science Advances</i> , 2022, 8, . | 4.7 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 964 | AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021â€“2022. <i>Jammi</i> , 2022, 7, 163-169. | 0.3 | 0 |
| 965 | Temporal Dynamics of Host Immune Response Associated With Disease Severity and Time to Recovery in Patients Hospitalized for COVID-19. , 2022, 4, e0760. | | 2 |
| 966 | COVID-19 Therapies for inpatients: a review and quality assessment of clinical guidelines. <i>ERJ Open Research</i> , 0, , 00236-2022. | 1.1 | 2 |
| 967 | PD-1/PD-L1 blockade abrogates a dysfunctional innate-adaptive immune axis in critical Î²-coronavirus disease. <i>Science Advances</i> , 2022, 8, . | 4.7 | 14 |
| 968 | Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. <i>Life</i> , 2022, 12, 1472. | 1.1 | 6 |
| 969 | Significant Publications on Infectious Diseases Pharmacotherapy in 2021. <i>Journal of Pharmacy Practice</i> , 2024, 37, 198-211. | 0.5 | 1 |
| 970 | A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 207, 261-270. | 2.5 | 25 |
| 971 | Risk stratification for selecting empiric antibiotherapy during and after COVID-19. <i>Current Opinion in Infectious Diseases</i> , 0, Publish Ahead of Print, . | 1.3 | 2 |
| 973 | Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial. <i>Medicine (United States)</i> , 2022, 101, e30618. | 0.4 | 3 |
| 974 | Failed clinical trials on COVID-19 acute respiratory distress syndrome in hospitalized patients: common oversights and streamlining the development of clinically effective therapeutics. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 995-1015. | 1.9 | 4 |
| 975 | Neuromuscular Blockade in the Pre- and COVID-19 ARDS Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 1538. | 1.1 | 7 |
| 976 | The effect of immunosuppressive therapy on the development of ventilator-associated pneumonia in patients with COVID-19. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 1252-1258. | 0.0 | 0 |
| 978 | Is Tocilizumab Plus Dexamethasone Associated with Superinfection in Critically Ill COVID-19 Patients?. <i>Journal of Clinical Medicine</i> , 2022, 11, 5559. | 1.0 | 2 |
| 979 | Recent advances in small-molecular therapeutics for COVID-19. <i>Precision Clinical Medicine</i> , 2022, 5, . | 1.3 | 9 |
| 980 | Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 0, , . | 2.9 | 82 |
| 981 | Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> ,the, 2022, 10, 1119-1128. | 5.2 | 4 |
| 982 | Care for adults with <sc>COVID</sc> â€“19: living guidelines from the National <sc>COVID</sc> â€“19 Clinical Evidence Taskforce. <i>Medical Journal of Australia</i> , 2022, 217, 368-378. | 0.8 | 8 |
| 983 | Anti-cytokine Therapy in Hospitalized Patients with COVID-19: The Jury is Out. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1069-1071. | 0.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 984 | Extracorporeal membrane oxygenation in COVID-19 associated acute respiratory distress syndrome: A narrative review. <i>Journal of Intensive Medicine</i> , 2023, 3, 4-10. | 0.8 | 2 |
| 985 | Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, . | 1.8 | 4 |
| 986 | Revisiting potential value of antitumor drugs in the treatment of COVID-19. <i>Cell and Bioscience</i> , 2022, 12, . | 2.1 | 1 |
| 987 | Managing Covid-19 in patients with heart failure: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 807-828. | 0.6 | 0 |
| 988 | SARS-CoV-2-induced hypomethylation of the ferritin heavy chain (FTH1) gene underlies serum hyperferritinemia in severe COVID-19 patients. <i>Biochemical and Biophysical Research Communications</i> , 2022, 631, 138-145. | 1.0 | 3 |
| 989 | Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1639-1644. | 0.8 | 1 |
| 992 | Progress, pitfalls, and path forward of drug repurposing for COVID-19 treatment. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211327. | 1.0 | 3 |
| 993 | From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?. <i>Biomedicines</i> , 2022, 10, 2620. | 1.4 | 6 |
| 994 | Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2238507. | 2.8 | 6 |
| 995 | Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 7 |
| 996 | Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study. <i>International Journal of Infectious Diseases</i> , 2022, 125, 233-240. | 1.5 | 4 |
| 997 | Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients. <i>Journal of Intensive Care Medicine</i> , 2023, 38, 70-77. | 1.3 | 2 |
| 998 | Utility of IL-6 in the Diagnosis, Treatment and Prognosis of COVID-19 Patients: A Longitudinal Study. <i>Vaccines</i> , 2022, 10, 1786. | 2.1 | 6 |
| 999 | Successful immunomodulators for the treatment of COVID-19 have opened the pathway for comparative trials. <i>Clinical Microbiology and Infection</i> , 2023, 29, 7-9. | 2.8 | 2 |
| 1000 | Digital Protein Detection in Bulk Solutions. <i>ACS Omega</i> , 2022, 7, 37714-37723. | 1.6 | 1 |
| 1001 | COVID-19-Associated Pulmonary Embolism: Review of the Pathophysiology, Epidemiology, Prevention, Diagnosis, and Treatment. <i>Seminars in Thrombosis and Hemostasis</i> , 2023, 49, 816-832. | 1.5 | 12 |
| 1002 | Factors predicting poor outcomes of patients treated with tocilizumab for COVID-19-associated pneumonia: A retrospective study. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, . | 0.8 | 5 |
| 1003 | Randomized Phase 3 Trial of Ruxolitinib for COVID-19-associated Acute Respiratory Distress Syndrome*. <i>Critical Care Medicine</i> , 2022, 50, 1701-1713. | 0.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1004 | Safety and Efficacy of Vidofludimus Calcium in Patients Hospitalized with COVID-19: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial. <i>Infectious Diseases and Therapy</i> , 2022, 11, 2159-2176. | 1.8 | 3 |
| 1005 | Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19. <i>BMJ Open</i> , 2022, 12, e060358. | 0.8 | 0 |
| 1006 | Immune Modulation in Sepsis, ARDS, and Covid-19 " The Road Traveled and the Road Ahead. , 2022, 1, . | | 6 |
| 1007 | Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. <i>Vaccines</i> , 2022, 10, 1673. | 2.1 | 1 |
| 1008 | MIF is a common genetic determinant of COVID-19 symptomatic infection and severity. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 205-212. | 0.2 | 6 |
| 1009 | Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, . | 1.6 | 8 |
| 1010 | Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52. | 4.1 | 67 |
| 1011 | Aviptadil for COVID-19: A Case Study and Call to Action About the Challenges of Research During a Global Pandemic*. <i>Critical Care Medicine</i> , 2022, 50, 1662-1664. | 0.4 | 0 |
| 1012 | Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. <i>Clinical Microbiology and Infection</i> , 2023, 29, 372-378. | 2.8 | 24 |
| 1013 | Management of hyperinflammation in COVID-19 patients. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 6-9. | 0.5 | 3 |
| 1014 | COVID-19 as a Risk Factor for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 1-23. | 1.2 | 10 |
| 1015 | Age- and Severity-Associated Humoral Immunity Response in COVID-19 Patients: A Cohort Study from Wuhan, China. <i>Journal of Clinical Medicine</i> , 2022, 11, 5974. | 1.0 | 1 |
| 1017 | Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*. <i>Critical Care Medicine</i> , 2022, 50, 1788-1798. | 0.4 | 13 |
| 1018 | Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. <i>PLoS Genetics</i> , 2022, 18, e1010367. | 1.5 | 21 |
| 1019 | Cytokine Release Syndrome and Sepsis. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 735-748. | 1.9 | 4 |
| 1020 | The Metabolomics of Critical Illness. <i>Handbook of Experimental Pharmacology</i> , 2022, , . | 0.9 | 0 |
| 1021 | V. Current Treatment Approach for COVID-19. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2374-2382. | 0.0 | 0 |
| 1022 | Pediatric Critical Care in the Twenty-first Century and Beyond. <i>Critical Care Clinics</i> , 2022, , . | 1.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1023 | Pathogenesis and histological changes of nephropathy associated with COVID-19. <i>Journal of Medical Virology</i> , 2023, 95, . | 2.5 | 5 |
| 1024 | COVID-19 in Russia: Evolution of Views on the Pandemic. Report II. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2022, 77, 291-306. | 0.2 | 2 |
| 1025 | Effective knowledge mobilisation: creating environments for quick generation, dissemination, and use of evidence. <i>BMJ, The</i> , 0, , e070195. | 3.0 | 1 |
| 1026 | Reply to Yan. <i>Clinical Infectious Diseases</i> , 0, , . | 2.9 | 0 |
| 1027 | COVID-19: From Pathophysiology to Treatment. , 0, , . | | 0 |
| 1028 | Identification of hospitalized mortality of patients with COVID-19 by machine learning models based on blood inflammatory cytokines. <i>Frontiers in Public Health</i> , 0, 10, . | 1.3 | 3 |
| 1030 | Randomized Open Investigation Determining Steroid Dose in Severe COVID-19: The ROIDS-Dose Clinical Trial. <i>Cureus</i> , 2022, , . | 0.2 | 1 |
| 1031 | Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand?. <i>Biomedicines</i> , 2022, 10, 2815. | 1.4 | 3 |
| 1032 | The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2022. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, , . | 0.6 | 0 |
| 1033 | Investigating the association between IL-6 antagonist therapy and blood coagulation in critically ill patients with COVID-19: a protocol for a prospective, observational, multicentre study. <i>BMJ Open</i> , 2022, 12, e063856. | 0.8 | 0 |
| 1034 | TriTECM: A tetrafunctional T-cell engaging antibody with built-in risk mitigation of cytokine release syndrome. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 2 |
| 1035 | Evaluation of the Prevalence of Barotrauma and Affecting Factors in Patients with COVID-19 during Follow-Up in the Intermediate Care Unit. <i>Journal of Personalized Medicine</i> , 2022, 12, 1863. | 1.1 | 0 |
| 1036 | De novo pancytopenia in an older adult with severe COVID-19 infection. <i>BMJ Case Reports</i> , 2022, 15, e252609. | 0.2 | 1 |
| 1037 | Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2. <i>British Journal of Pharmacology</i> , 2023, 180, 133-143. | 2.7 | 2 |
| 1038 | GM-CSF targeting in COVID-19: an approach based on fragile foundations. <i>European Respiratory Journal</i> , 2023, 61, 2202091. | 3.1 | 2 |
| 1039 | Immunomodulators in Mechanically Ventilated Patients With COVID-19: Lessons Learned From Underpowered Trials*. <i>Critical Care Medicine</i> , 2022, 50, 1821-1828. | 0.4 | 1 |
| 1040 | Human Coronaviruses. , 2023, , 1167-1175.e6. | | 0 |
| 1042 | Pituitary-gonadal hormones associated with respiratory failure in men and women hospitalized with COVID-19: an observational cohort study. <i>Endocrine Connections</i> , 2023, 12, . | 0.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1043 | Interleukin-6 Targeted Agents. , 2022, , 187-197. | | 0 |
| 1044 | Immune-Targeted Therapies for COVID-19. , 2022, , 451-468. | | 0 |
| 1045 | COVID-19 pandemic: the impact on Canadaâ€™s intensive care units. Facets, 2022, 7, 1411-1472. | 1.1 | 3 |
| 1046 | Severe Coronavirus disease (COVID)-19: from pathogenesis to therapy. Shock, 0, Publish Ahead of Print, . | 1.0 | 0 |
| 1047 | IS TOCILIZUMAB AN EFFECTIVE THERAPY FOR SEVERE COVID-19: A SINGLE CENTER STUDY. Journal of Ayub Medical College, Abbottabad: JAMC, 2022, 34, 751-758. | 0.1 | 0 |
| 1048 | Effectiveness and safety of tocilizumab for COVID-19: a systematic review and meta-analysis of randomized clinical trials. Sao Paulo Medical Journal, 2023, 141, 168-176. | 0.4 | 2 |
| 1050 | The evolving landscape of pulmonary arterial hypertension clinical trials. Lancet, The, 2022, 400, 1884-1898. | 6.3 | 25 |
| 1051 | Utility of the HScore for Predicting COVID-19 Severity. Cureus, 2022, , . | 0.2 | 0 |
| 1052 | Targeting the Complementâ€™Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. International Journal of Molecular Sciences, 2022, 23, 14340. | 1.8 | 7 |
| 1053 | Could treatment with immunomodulatory agents targeting IL-1, IL-6, or JAK signalling improve outcomes in patients with severe influenza pneumonia? A systematic and narrative review. HRB Open Research, 0, 5, 77. | 0.3 | 1 |
| 1054 | The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies. International Journal of Molecular Sciences, 2022, 23, 14914. | 1.8 | 5 |
| 1055 | Platform trials for anaesthesia and perioperative medicine: a narrative review. British Journal of Anaesthesia, 2023, 130, 677-686. | 1.5 | 3 |
| 1056 | Antiviral Treatment of COVID-19 Pneumonia. Clinics in Chest Medicine, 2022, , . | 0.8 | 0 |
| 1057 | Cannabinoids as Immune System Modulators: Cannabidiol Potential Therapeutic Approaches and Limitations. Cannabis and Cannabinoid Research, 0, , . | 1.5 | 3 |
| 1058 | Immunomodulatory agents for COVID-19 pneumonia. Clinics in Chest Medicine, 2022, , . | 0.8 | 1 |
| 1059 | N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro. International Journal of Molecular Sciences, 2022, 23, 14518. | 1.8 | 11 |
| 1060 | SARS-CoV-2 Infection and COVID-19 in Children. Clinics in Chest Medicine, 2023, 44, 359-371. | 0.8 | 6 |
| 1061 | Pathological Roles of Pulmonary Cells in Acute Lung Injury: Lessons from Clinical Practice. International Journal of Molecular Sciences, 2022, 23, 15027. | 1.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1062 | Liposomal amphotericin B—the future. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, ii21-ii34. | 1.3 | 5 |
| 1063 | Pathological Lung Patterns of COVID-19 and its Clinical Correlation to Disease Severity. <i>Indian Journal of Critical Care Medicine</i> , 2022, 26, 1285-1292. | 0.3 | 2 |
| 1064 | Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1716-1727. | 2.0 | 2 |
| 1065 | Estimating causal effects of genetically predicted type 2 diabetes on COVID-19 in the East Asian population. <i>Frontiers in Endocrinology</i> , 0, 13, . | 1.5 | 2 |
| 1066 | Encephalopathy in 2 paediatric patients with SARS-CoV-2 infection benefited from early immunosuppressive treatment: a case report. <i>Neuroimmunology Reports</i> , 2022, , 100162. | 0.2 | 0 |
| 1067 | Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19. <i>JAMA Network Open</i> , 2022, 5, e2242918. | 2.8 | 2 |
| 1068 | Therapeutic Polypeptides and Peptidomimetics: Powerful Tools for COVID-19 Treatment. <i>Clinical Drug Investigation</i> , 2023, 43, 13-22. | 1.1 | 1 |
| 1069 | A leap towards personalised therapy of acute lung injury. <i>European Respiratory Journal</i> , 2022, 60, 2201808. | 3.1 | 1 |
| 1070 | Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 39. | 3.8 | 64 |
| 1071 | Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. <i>Nature Communications</i> , 2022, 13, . | 5.8 | 13 |
| 1073 | ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. <i>Trials</i> , 2022, 23, . | 0.7 | 4 |
| 1075 | Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?. <i>Drugs</i> , 2023, 83, 1-36. | 4.9 | 4 |
| 1077 | AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118. | 1.3 | 2 |
| 1078 | Clinical outcomes of COVID-19 caused by the Alpha variant compared with one by wild type in Kobe, Japan. A multi-center nested case-control study. <i>Journal of Infection and Chemotherapy</i> , 2022, , . | 0.8 | 0 |
| 1079 | Age and Comorbidities Predict COVID-19 Outcome, Regardless of Innate Immune Response Severity: A Single Institutional Cohort Study. , 2022, 4, e0799. | | 4 |
| 1080 | Management of Coronavirus Disease-2019 Infection in Pregnancy. <i>Emergency Medicine Clinics of North America</i> , 2023, 41, 307-322. | 0.5 | 0 |
| 1081 | Identification of two specific transcriptomic clusters of COVID-19 ARDS patients with different immune profiles and different outcomes. <i>European Respiratory Journal</i> , 0, , 2202008. | 3.1 | 0 |
| 1082 | Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease. <i>Blood Advances</i> , 0, , . | 2.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1083 | Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. <i>Health Research Policy and Systems</i> , 2022, 20, . | 1.1 | 3 |
| 1084 | Platform trials. <i>Therapie</i> , 2023, 78, 29-38. | 0.6 | 4 |
| 1085 | An epithelial-immune circuit amplifies inflammasome and IL-6 responses to SARS-CoV-2. <i>Cell Host and Microbe</i> , 2023, 31, 243-259.e6. | 5.1 | 20 |
| 1086 | Patient and public involvement in contemporary large intensive care trials: A meta-epidemiological study. <i>Acta Anaesthesiologica Scandinavica</i> , 2023, 67, 256-263. | 0.7 | 2 |
| 1087 | Development and validation of a predictive scoring system for in-hospital mortality in COVID-19 Egyptian patients: a retrospective study. <i>Scientific Reports</i> , 2022, 12, . | 1.6 | 2 |
| 1088 | Immune-based therapy for hospitalized patients with COVID-19 and risk of secondary infections: A systematic review and meta-analysis. <i>Open Forum Infectious Diseases</i> , 0, , . | 0.4 | 1 |
| 1089 | Effect of tocilizumab treatment in mildly-obese patients with coronavirus disease 2019: a case series. <i>Annals of Translational Medicine</i> , 2022, 10, 1263-1263. | 0.7 | 2 |
| 1090 | Gaps and opportunities in sepsis translational research. <i>EBioMedicine</i> , 2022, 86, 104387. | 2.7 | 6 |
| 1091 | Target Trial Emulation. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 2446. | 3.8 | 106 |
| 1092 | Utility of lung ultrasound in selecting older patients with hyperinflammatory phase in COVID-19 pneumonia. A monocentric, cross-sectional pilot study. <i>Journal of Gerontology and Geriatrics</i> , 0, , 1-7. | 0.2 | 0 |
| 1093 | Long-term Follow-up After Critical COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 0, , . | 3.8 | 4 |
| 1094 | Lymphopenia in sepsis—an acquired immunodeficiency?. <i>Immunology and Cell Biology</i> , 2023, 101, 535-544. | 1.0 | 12 |
| 1095 | Major Publications in the Critical Care Pharmacotherapy Literature: 2021. , 2022, 4, e0823. | | 1 |
| 1096 | Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France. <i>Antibiotics</i> , 2023, 12, 88. | 1.5 | 1 |
| 1097 | HIV and COVID-19 Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 035-049. | 0.8 | 2 |
| 1098 | Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital With a Predominantly Hispanic/Latino Adult Population. <i>Open Forum Infectious Diseases</i> , 2023, 10, . | 0.4 | 3 |
| 1099 | Wearable and flexible electrochemical sensors for sweat analysis: a review. <i>Microsystems and Nanoengineering</i> , 2023, 9, . | 3.4 | 98 |
| 1100 | Fire in the belly: A scoping review of the immunopathological mechanisms of acute pancreatitis. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 4 |

| # | ARTICLE | IF | CITATIONS |
|------|---|------|-----------|
| 1101 | Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19. <i>Science Advances</i> , 2023, 9, . | 4.7 | 6 |
| 1102 | A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia. <i>Inflammation and Regeneration</i> , 2023, 43, . | 1.5 | 8 |
| 1104 | Innate immune evasion strategies of SARS-CoV-2. <i>Nature Reviews Microbiology</i> , 0, , . | 13.6 | 31 |
| 1105 | Infectious complications after tocilizumab in patients with COVID: a real-world experience. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2023, 13, . | 0.4 | 1 |
| 1106 | The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19. <i>Transplant Immunology</i> , 2023, 77, 101777. | 0.6 | 0 |
| 1107 | Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 446-459. | 0.2 | 0 |
| 1112 | Reply: Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211449. | 0.9 | 0 |
| 1113 | Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. <i>PLoS Medicine</i> , 2023, 20, e1004086. | 3.9 | 24 |
| 1114 | Innate immune responses in COVID-19. , 2023, , 63-128. | | 0 |
| 1115 | Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. , 2023, , 99-139. | | 1 |
| 1116 | Maternal and Fetal Outcome in Pregnant Women With Critical COVID-19 Treated With Tocilizumab in a Tertiary Care Hospital in Dubai. <i>Cureus</i> , 2023, , . | 0.2 | 0 |
| 1117 | Evaluation of Early Tocilizumab Effect on Multiorgan Dysfunction in Critically Ill Patients With COVID-19: A Propensity Score-Matched Study. <i>Journal of Intensive Care Medicine</i> , 2023, 38, 534-543. | 1.3 | 1 |
| 1118 | Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian randomisation study. <i>PLoS Medicine</i> , 2023, 20, e1004174. | 3.9 | 25 |
| 1119 | Enoxaparin Posology According to Prothrombotic Status and Bleeding Risk in Hospitalized Patients with SARS-CoV-2 Pneumonia. <i>Journal of Clinical Medicine</i> , 2023, 12, 928. | 1.0 | 0 |
| 1120 | Inflammatory and vascular biomarkers in postâ€COVIDâ€19 syndrome: A systematic review and metaâ€analysis of over 20 biomarkers. <i>Reviews in Medical Virology</i> , 2023, 33, . | 3.9 | 30 |
| 1121 | Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study. <i>Viruses</i> , 2023, 15, 294. | 1.5 | 2 |
| 1122 | Microvascular Thrombosis as a Critical Factor in Severe COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2492. | 1.8 | 10 |
| 1123 | Combating the challenges of COVID-19 pandemic: Insights into molecular mechanisms, immune responses and therapeutics against SARS-CoV-2. <i>Oxford Open Immunology</i> , 2023, 4, . | 1.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1124 | Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles. <i>JAMA Network Open</i> , 2023, 6, e2253301. | 2.8 | 0 |
| 1125 | Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia. <i>Medicina Clínica (English Edition)</i> , 2023, , . | 0.1 | 0 |
| 1126 | Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*. <i>Critical Care Medicine</i> , 2023, 51, 337-346. | 0.4 | 11 |
| 1127 | Inflammation and corticosteroids in acute heart failure. <i>European Journal of Emergency Medicine</i> , 2023, 30, 65-66. | 0.5 | 2 |
| 1128 | Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2023, 10, . | 0.4 | 0 |
| 1129 | Obliterative Endotheliitis Leading to Cystic Lung Necrosis in Severe COVID-19 during the First Wave of the Pandemic. <i>BioMed</i> , 2023, 3, 202-206. | 0.6 | 0 |
| 1130 | Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 20 |
| 1131 | Corticosteroid outcome may be dependent of duration of use in severe COVID-19. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 382-392. | 0.7 | 4 |
| 1132 | SARS-CoV-2-Induced Myocarditis: A State-of-the-Art Review. <i>Viruses</i> , 2023, 15, 916. | 1.5 | 3 |
| 1133 | Methodology and design of platform trials: a meta-epidemiological study. <i>Journal of Clinical Epidemiology</i> , 2023, 157, 1-12. | 2.4 | 4 |
| 1134 | Beneficial effects of L-Arginine in patients hospitalized for COVID-19: New insights from a randomized clinical trial. <i>Pharmacological Research</i> , 2023, 191, 106702. | 3.1 | 9 |
| 1135 | Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy. <i>Journal of Critical Care</i> , 2023, 76, 154272. | 1.0 | 6 |
| 1136 | Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure. <i>Journal of Critical Care</i> , 2023, 76, 154291. | 1.0 | 0 |
| 1137 | Procalcitonin Values Fail to Track the Presence of Secondary Bacterial Infections in COVID-19 ICU Patients. <i>Antibiotics</i> , 2023, 12, 709. | 1.5 | 2 |
| 1138 | Impact of Vaccination on Cost and Course of Hospitalization Associated with COVID-19 Infection. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2023, 3, . | 0.2 | 1 |
| 1139 | Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study. <i>Biomedicines</i> , 2023, 11, 349. | 1.4 | 1 |
| 1140 | A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages. <i>International Journal of Infectious Diseases</i> , 2023, 129, 57-62. | 1.5 | 1 |
| 1141 | The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, . | 1.1 | 17 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1142 | Therapeutic options in COVID-19. , 2023, , 647-672. | | 0 |
| 1143 | Impact of COVID-19 on Cardiovascular Disease. <i>Viruses</i> , 2023, 15, 508. | 1.5 | 15 |
| 1144 | A 64-Year-Old Man Hospitalized for COVID-19 Pneumonia and Treated with Tocilizumab Who Developed Chronic Cavitory Pulmonary Aspergillosis. <i>American Journal of Case Reports</i> , 0, 24, . | 0.3 | 2 |
| 1145 | Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more. <i>British Journal of Clinical Pharmacology</i> , 0, , . | 1.1 | 0 |
| 1146 | Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome. <i>PLoS ONE</i> , 2023, 18, e0280677. | 1.1 | 2 |
| 1147 | Drug target Mendelian randomisation: are we really instrumenting drug use?. <i>Diabetologia</i> , 2023, 66, 1156-1158. | 2.9 | 5 |
| 1148 | Current and Emerging Therapies for COVID-19 in Lung Transplantation. <i>Current Pulmonology Reports</i> , 2023, 12, 23-35. | 0.5 | 1 |
| 1149 | Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. <i>Viruses</i> , 2023, 15, 549. | 1.5 | 3 |
| 1150 | Insights into COVID-19-associated critical illness: a narrative review. <i>Annals of Translational Medicine</i> , 2023, 11, 220-220. | 0.7 | 2 |
| 1151 | Severe COVID-19-associated hyperinflammatory syndrome versus classic hemophagocytic lymphohistiocytosis: similarities, differences, and the way forward. <i>Journal of Investigative Medicine</i> , 2023, 71, 244-253. | 0.7 | 0 |
| 1153 | Strongyloides and COVID-19: Challenges and Opportunities for Future Research. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 127. | 0.9 | 2 |
| 1154 | Risk of Underlying Diseases and Effectiveness of Drugs on COVID-19 Inpatients Assessed Using Medical Claims in Japan: Retrospective Observational Study. <i>International Journal of General Medicine</i> , 0, Volume 16, 657-672. | 0.8 | 2 |
| 1155 | Inhaled ciclesonide in adults hospitalised with COVID-19: a randomised controlled open-label trial (HALT COVID-19). <i>BMJ Open</i> , 2023, 13, e064374. | 0.8 | 5 |
| 1156 | Comparison of systemic inflammatory profiles in COVID-19 and community-acquired pneumonia patients: a prospective cohort study. <i>Respiratory Research</i> , 2023, 24, . | 1.4 | 3 |
| 1157 | Association Between Metabolic Syndrome Inflammatory Biomarkers and COVID-19 Severity. <i>Journal of the Endocrine Society</i> , 2023, 7, . | 0.1 | 0 |
| 1158 | Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4401. | 1.8 | 4 |
| 1159 | Elevated free interleukin-18 associated with severity and mortality in prospective cohort study of 206 hospitalised COVID-19 patients. <i>Intensive Care Medicine Experimental</i> , 2023, 11, . | 0.9 | 7 |
| 1160 | The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2022, 9, 17-32. | 0.3 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|---|-----|-----------|
| 1161 | Integrated Metabolic and Inflammatory Signatures Associated with Severity of, Fatality of, and Recovery from COVID-19. <i>Microbiology Spectrum</i> , 2023, 11, . | 1.2 | 4 |
| 1162 | Thrombosis, Inflammation, and Lipoprotein(a): Clinical Implications. <i>Contemporary Cardiology</i> , 2023, , 189-206. | 0.0 | 0 |
| 1163 | Treating COVID-19: Targeting the Host Response, Not the Virus. <i>Life</i> , 2023, 13, 712. | 1.1 | 2 |
| 1164 | Antivirals for adult patients hospitalised with SARS-CoV-2 infection: a randomised, phase II/III, multicentre, placebo-controlled, adaptive study, with multiple arms and stages. COALITION COVID-19 BRAZIL IX "REVOLUTION" trial. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100466. | 1.5 | 1 |
| 1165 | Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study). <i>EClinicalMedicine</i> , 2023, 57, 101895. | 3.2 | 1 |
| 1166 | Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone. <i>Infectious Diseases</i> , 2023, 55, 351-360. | 1.4 | 3 |
| 1167 | Anti-cytokine Therapy in Critical Illness: Is There a Role?. <i>Lessons From the ICU</i> , 2023, , 277-297. | 0.1 | 0 |
| 1168 | Hemophagocytic Syndrome and COVID-19: A Comprehensive Review. <i>Cureus</i> , 2023, , . | 0.2 | 0 |
| 1169 | Secondary infections in critically ill patients with viral pneumonia due to COVID-19 and influenza: a historical cohort study. <i>Canadian Journal of Anaesthesia</i> , 2023, 70, 374-383. | 0.7 | 1 |
| 1170 | Tocilizumab Outcomes in Critically Ill COVID-19 Patients Admitted to the ICU and the Role of Non-Tocilizumab COVID-19-Specific Medical Therapeutics. <i>Journal of Clinical Medicine</i> , 2023, 12, 2301. | 1.0 | 0 |
| 1171 | COVID-19 in Elderly Patients Receiving Haemodialysis: A Current Review. <i>Biomedicines</i> , 2023, 11, 926. | 1.4 | 2 |
| 1172 | Clinical Characteristics of Strongyloidiasis during the COVID-19 Pandemic: Systematic Scoping Review. <i>American Journal of Tropical Medicine and Hygiene</i> , 2023, , . | 0.6 | 0 |
| 1174 | COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices. <i>Viruses</i> , 2023, 15, 787. | 1.5 | 5 |
| 1175 | Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 475-493. | 1.9 | 1 |
| 1176 | Mortality Predictors of Pre-variant SARS-CoV-2 Infected ARDS Patients Receiving Favipiravir and Tocilizumab. <i>Current Respiratory Medicine Reviews</i> , 2023, 19, . | 0.1 | 0 |
| 1177 | Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study. <i>PLoS ONE</i> , 2023, 18, e0283529. | 1.1 | 0 |
| 1178 | Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. <i>Journal of Inflammation</i> , 2023, 20, . | 1.5 | 2 |
| 1179 | Cytokine Storm Syndromes in Pediatric Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, , . | 2.0 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1180 | Association of <i>ACE</i> ID, <i>MTHFR</i> C677T, and <i>MIF</i> -173GC variants with the clinical course of COVID-19 patients. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2023, 42, 782-796. | 0.4 | 1 |
| 1181 | Advances in the study of myeloid-derived suppressor cells in infectious lung diseases. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 1 |
| 1182 | Characterisation of the pro-inflammatory cytokine signature in severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 4 |
| 1183 | Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. <i>World Journal of Clinical Cases</i> , 0, 11, 2140-2159. | 0.3 | 1 |
| 1184 | Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. <i>Clinical Infectious Diseases</i> , 2023, 77, 186-193. | 2.9 | 1 |
| 1185 | Pathophysiology of COVID-19 pneumonia and respiratory treatment. <i>Minerva Anestesiologica</i> , 2023, 89, . | 0.6 | 1 |
| 1186 | COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic. <i>Biology</i> , 2023, 12, 545. | 1.3 | 2 |
| 1187 | Different degree of cytokinemia and T-cell activation according to serum IL-6 levels in critical COVID-19. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 0 |
| 1188 | Longitudinal Trends in Cardiovascular Risk Factor Profiles and Complications Among Patients Hospitalized for COVID-19 Infection: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2023, 16, . | 0.9 | 2 |
| 1189 | Host-Based Treatments for Severe COVID-19. <i>Current Issues in Molecular Biology</i> , 2023, 45, 3102-3121. | 1.0 | 3 |
| 1190 | Immunology of COVID-19. , 2024, , 52-71. | | 0 |
| 1191 | Kidney Manifestations of COVID-19. , 2024, , 203-217. | | 0 |
| 1192 | Treatment options for patients with severe COVID-19. <i>Global Health & Medicine</i> , 2023, 5, 99-105. | 0.6 | 1 |
| 1193 | Investigational medications in 9,638 hospitalized patients with severe COVID-19: lessons from the “fail-and-learn” strategy during the first two waves of the pandemic in 2020. <i>Patient Safety in Surgery</i> , 2023, 17, . | 1.1 | 0 |
| 1194 | The positive impact of COVID-19 on critical care: from unprecedented challenges to transformative changes, from the perspective of young intensivists. <i>Annals of Intensive Care</i> , 2023, 13, . | 2.2 | 2 |
| 1195 | Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support—Free Days in Patients Hospitalized With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2023, 329, 1183. | 3.8 | 19 |
| 1196 | Cytokine storm—based mechanisms for extrapulmonary manifestations of SARS-CoV-2 infection. <i>JCI Insight</i> , 2023, 8, . | 2.3 | 2 |
| 1197 | Cytoplasmic DNAs: Sources, sensing, and roles in the development of lung inflammatory diseases and cancer. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 1 |

| # | ARTICLE | IF | CITATIONS |
|------|--|------|-----------|
| 1198 | Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now. <i>Frontiers in Pharmacology</i> , 0, 14, . | 1.6 | 9 |
| 1199 | A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19. <i>Transfusion and Apheresis Science</i> , 2023, 62, 103712. | 0.5 | 1 |
| 1200 | Drug effectiveness for COVID-19 inpatients inferred from Japanese medical claim data using propensity score matching. <i>F1000Research</i> , 0, 12, 398. | 0.8 | 1 |
| 1201 | Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial. <i>BMJ Open</i> , 2023, 13, e068179. | 0.8 | 1 |
| 1202 | Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients. <i>Journal of Hematology and Oncology</i> , 2023, 16, . | 6.9 | 4 |
| 1203 | Targeting IL-6 trans-signalling: past, present and future prospects. <i>Nature Reviews Immunology</i> , 2023, 23, 666-681. | 10.6 | 46 |
| 1204 | Vitamin D as a prognostic biomarker in COVID-19: single-center study and meta-analyses. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2023, 83, 173-182. | 0.6 | 0 |
| 1205 | Severe COVID-19: Drugs and Clinical Trials. <i>Journal of Clinical Medicine</i> , 2023, 12, 2893. | 1.0 | 0 |
| 1206 | Epidural Abscesses as a Complication of Interleukin-6 Inhibitor and Dexamethasone Treatment in a Patient with COVID-19 Pneumonia: A Case Report. <i>Medicina (Lithuania)</i> , 2023, 59, 771. | 0.8 | 1 |
| 1207 | The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical). <i>Journal of Interferon and Cytokine Research</i> , 2023, 43, 147-163. | 0.5 | 7 |
| 1208 | Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 2 |
| 1209 | Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475. | 21.5 | 112 |
| 1210 | Artificial intelligence in critical illness and its impact on patient care: a comprehensive review. <i>Frontiers in Medicine</i> , 0, 10, . | 1.2 | 7 |
| 1211 | In the SARS-CoV-2 Pandora Pandemic: Can the Stance of Premorbid Intestinal Innate Immune System as Measured by Fecal Adnab-9 Binding of p87:Blood Ferritin, Yielding the FERAD Ratio, Predict COVID-19 Susceptibility and Survival in a Prospective Population Database?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7536. | 1.8 | 2 |
| 1213 | COVID-19 and Multiorgan Response: The Long-Term Impact. <i>Current Problems in Cardiology</i> , 2023, 48, 101756. | 1.1 | 2 |
| 1214 | [Translated article] Efficacy and marginal cost of treatment with tocilizumab in COVID-19 patients. <i>Farmacia Hospitalaria</i> , 2023, 47, T10-T15. | 0.6 | 0 |
| 1238 | Comorbid Obesity and Its Impact on Diabetes and COVID-19. <i>Contemporary Endocrinology</i> , 2023, , 93-107. | 0.3 | 0 |
| 1249 | Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , . | 1.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|------|--|-----|-----------|
| 1260 | Effectiveness of tocilizumab in non-intubated cases with COVID-19: a systematic review and meta-analysis. <i>Infection</i> , 0, , . | 2.3 | 2 |
| 1264 | Antiviral Drugs for SARS-CoV-2 and COVID-19. , 2023, , 211-223. | | 0 |
| 1309 | The role of cell death in SARS-CoV-2 infection. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, . | 7.1 | 4 |
| 1360 | Immunoregulatory nanomedicine for respiratory infections. , 0, , . | | 0 |
| 1376 | SARS-CoV-2 Spike Protein: A Review of Structure, Function, Care, Vaccines, and Possible Inhibitors Designed by Molecular Modeling. <i>Engineering Materials</i> , 2024, , 271-289. | 0.3 | 0 |
| 1381 | Chemical and physiological effects of dexamethasone drug to hyperglycemia with Covid-19 patients. <i>AIP Conference Proceedings</i> , 2023, , . | 0.3 | 0 |
| 1389 | The pathophysiology of sepsis and precision-medicine-based immunotherapy. <i>Nature Immunology</i> , 2024, 25, 19-28. | 7.0 | 1 |
| 1390 | Cytokine storm in COVID-19 and other diseases: emerging therapeutic interventions. , 2024, , 209-241. | | 0 |